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ABSTRACT 
The role of gene regulation in cancer: Studies of cancer-related phenotypes mediated 
by MEX3D and by microRNA-618 implicate their potential oncogenic role 
 
Travis Michael Whitfill 
 
2014 
 
The control of gene expression is pivotal in the context of molecular 
pathogenesis of a number of diseases, and thus is of critical relevance to public health. 
An array of cellular tools exist in controlling gene expression, including epigenetic 
effects, non-coding RNAs, and RNA-binding proteins. These tools are critical to the 
modern study of public health, and are used in tandem with population-based studies. 
This work focuses on specific examples of non-coding RNAs and RNA-binding 
proteins, describing the effects of microRNA-618, a non-coding RNA, and MEX3D, 
a post-transcriptional regulator, in cancer.  
MicroRNAs (miRNAs) form a class of highly conserved endogenous RNAs 
that inhibit gene expression and may act as oncogenes or as tumor suppressors, 
regulating extensive cancer-related gene networks. Here, we show the association 
between a single miRNA, miR-618, and cancer-related pathways in HeLa cells. MiR-
618 was identified as a potentially oncogenic microRNA, controlling a number of 
cancer-related gene networks and pathways. Gain-of-function analysis reveals 
differential expression of 110 transcripts following miRNA-618 transfection. Notably, 
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three upregulated genes are well-studied oncogenes—KIT, JUN, and FOSB—and 
three downregulated genes are well-known tumor suppressors—PTPRO, 
STK11/LKB1, and IGFBP5. Interestingly, investigation using the Ingenuity Pathway 
Analysis software tool reveals alterations in multiple cancer-related and cell cycle-
related networks, including upregulated oncogenes in the top identified network 
“Post-translational modification, cellular development, cellular growth and 
proliferation” following miR-618 transfection. Further, miR-618 expression analysis 
shows overexpression in HeLa cells compared to normal cervical cells. Our findings 
present evidence for a novel oncogenic miRNA, miR-618, that is involved in cancer-
related gene networks and is overexpressed in cancer. 
 This work also examined the role of a novel post-transcriptional regulator, 
MEX3D, in cancer. The Oncomine online database reveals that MEX3D is 
overexpressed in a number of solid tumors, notably in glioma. MEX3D is 3.01-fold 
overexpressed in glioma cells compared to non-cancerous, normal tissue. Kaplan-
Meier survival analysis reveals that higher expression of MEX3D leads to poorer 
overall survival in overall glioma patients. Lastly, in a pilot case-control study of 
twelve glioma biopsies, we examined the effects of methylation in CpG sites in the 
MEX3D gene. The results were unclear, as we found a 3’UTR site that was 9.5% 
hypermethylated compared to normal tissue, a site in the body of the gene that was 
24.8% hypermethylated, and second site in the body that was 15.4% hypomethylated 
compared to normal tissue. 
Phenotypic studies reveal that MEX3D is responsible for two cancer 
phenotypes. Knockdown of MEX3D leads to increased cell proliferation and 
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decreased cell invasion, suggesting that overexpression of MEX3D is responsible for 
increased cell proliferation and decreased cell invasion.  
 This study is the first to describe the effects of miR-618 and of MEX3D in 
cancer. The findings presented in this work lay the foundation for further mechanistic 
studies of miR-618 and MEX3D. More work is needed to identify the mechanisms of 
oncogenesis controlled by these molecules. Our study indicates that miR-618 may be 
a biomarker for several types of cancer and warrants further investigation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
ACKNOWLEDGEMENTS 
 
“Yale is at once a tradition, a company of scholars, a society of friends.”  
-- George Pierson, Yale College 
 
Being at Yale has been a transformative experience in ways I did not foresee 
before starting my studies at Yale. In my two short years at this great University, I 
have made valuable connections, lasting friendships, and unforgettable memories. I 
owe everything in this work and the trajectory of my career path to this institution, 
and for those reasons, I am forever grateful for the opportunity to be here. Yale is full 
of incredible scholars from all across the world, and I am eternally appreciative to 
have been a part of the collective body of scholars at Yale—albeit a short period of 
two years.    
I’d like to first thank my advisor, Yong Zhu, for his continuous support over 
the last two years. I am grateful to have had the opportunity to study in his lab, and I 
am glad to have found a lab in which the research encompasses so many aspects of 
medical research, from population-based research to intricate molecular studies. The 
members in his lab have been instrumental in this project. I’d especially like to thank 
Daniel Jacobs for his help in this work. He has spent many hours helping me, guiding 
me, and advising me, and I have thoroughly enjoyed working with him. He 
contributed to the design and execution of a number of the experiments represented in 
this thesis.  
 7 
I would like to thank other members of the lab as well, especially Alan Fu. He 
has also been instrumental in the success of this thesis. His intellectual contributions 
fueled a number of aspects of this thesis. I’d also like to thank Allison Fritz for the 
expression analysis of miR-618 in HeLa cells.  
Lastly, I would not be here without the support of my friends, both old and 
new, from home and here at Yale. They have gotten me through the drudgery of grad 
school and have provided moral support for which I am very thankful.  
Funding 
This work was supported by the National Institutes of Health grant CA122676.  
It was also partially supported by the Yale School of Public Health Dull Family 
Summer Internship Fellowship. Many thanks to the Dull Family for financial support 
over the summer or 2013, which directly contributed to the works presented in this 
thesis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
TABLE OF CONTENTS 
ABSTRACT .................................................................................................................. 3 
ACKNOWLEDGEMENTS .......................................................................................... 6 
LIST OF FIGURES ..................................................................................................... 10 
LIST OF TABLES ...................................................................................................... 11 
CHAPTER 1: INTRODUCTION ............................................................................... 14 
1.1 Function of microRNAs ............................................................................ 15 
1.2 Role of miRNAs in cancer ........................................................................ 16 
1.3 Effects of DNA methylation in cancer ...................................................... 17 
1.4 RNA binding proteins and disease relevance ............................................ 18 
1.5 MEX-3 ....................................................................................................... 20 
1.6 Disease relevance of MEX-3 family ......................................................... 21 
1.7 Epidemiology and clinical characterization of glioma .............................. 23 
CHAPTER 2: MIR-618 DISPLAYS POSSIBLE ONCOGENIC ACTIVITY ........... 33 
2.1 INTRODUCTION ..................................................................................... 33 
2.2 RESULTS .................................................................................................. 34 
2.3 DISCUSSION ........................................................................................... 36 
CHAPTER 3: MEX3D IS OVEREXPRESSED ACROSS CANCER TYPES .......... 50 
3.1: INTRODUCTION .................................................................................... 50 
3.2 RESULTS .................................................................................................. 52 
3.3 DISCUSSION ........................................................................................... 55 
CHAPTER 4: MEX3D IS AN ONCOGENE IN GLIOMA ........................................ 63 
4.1 INTRODUCTION ..................................................................................... 63 
4.2 RESULTS .................................................................................................. 65 
4.3 DISCUSSION ........................................................................................... 67 
CHAPTER 5: CONCLUSIONS .................................................................................. 81 
CHAPTER 6: Materials and methods ......................................................................... 84 
6.1 Cell culture and miRNA transfection (Chapters 2 and 4) ......................... 84 
6.2 miRNA transfection (Chapter 2) ............................................................... 84 
 9 
6.3 Genome-wide expression microarray (Chapter 2) .................................... 85 
6.4 Network Analysis (Chapter 2) ................................................................... 85 
6.5 Expression analysis of miR-618 (Chapter 2) ............................................ 86 
6.6 Oncomine Database Search (Chapters 3 and 4) ........................................ 86 
6.7 Kaplan-Meier curve (Chapter 4) ............................................................... 87 
6.8 MEX3D methylation analysis (Chapter 4) ................................................ 87 
6.9 RNA interference and cell transfection (Chapter 4) .................................. 88 
6.10 Cell proliferation assay (Chapter 4) ........................................................ 89 
6.11 Cell invasion assay (Chapter 4) ............................................................... 89 
6.12 Statistical analysis ................................................................................... 90 
CHAPTER 7: SUPPLEMENTARY INFORMATION .............................................. 91 
CHAPTER 8: REFERENCES .................................................................................. 105 
 
 
 
 
 
 
 
 
 
 
 10 
LIST OF FIGURES 
Figure 1.1 Role of miRNAs in gene expression (p. 25) 
Figure 1.2 Role of miRNAs in molecular carcinogenesis (p.27) 
Figure 1.3 Schematic of mRNA in humans regulation of post-transcriptional activity 
(p. 30) 
Figure 1.4 Structure of the KH domain (p. 31) 
Figure 2.1 Cancer-related functions of selected differentially expressed genes (p. 44) 
Figures 2.2 Differentially expressed genes in the “Post-transcriptional modification, 
cellular development, and cellular growth and proliferation” network (p. 46) 
Figure 2.3 miR-618 is overexpressed in HeLa cells relative to End1 cells (p. 48) 
Figure 3.1 Overexpression of MEX3D in tumors (p. 57) 
Figure 3.2 MEX4A-C are also overexpressed across tumor types (p. 59)  
Figure 4.1 MEX3D is overexpressed in glioma and leads to poor survival in glioma 
patients (p. 70) 
Figure 4.2 Methylation of CpG sites in MEX3D in glioma vs. normal samples (p. 72)  
Figure 4.3 Knockdown of MEX3D in A172 cells (p. 74)  
Figure 4.4 MEX3D knockdown decreases cell proliferation in A172 glioma cells (p. 
76)  
Figure 4.5 MEX3D knockdown increases cell invasion in A172 cells and U87 cells 
(p. 78)  
Figure S1 Secondary prediction structure of pre-miR-618 (p. 100) 
Figure S2 Differentially expressed transcripts following miR-618 transfection in the 
“Cellular movement, cell death and survival, and cell cycle” network. (p. 102) 
 11 
LIST OF TABLES 
Table 2.1 Top biological functions of differentially expressed targets of miR-618(p. 
40) 
Table 2.2  Identified cancer-related differentially expressed miR-618 targets (p. 44) 
Table 3.1 Expression profiles of MEX3A-D in cancer vs. normal tissue (p. 61) 
Supplementary Table S1 All identified differentially expressed genes by miR-618 
transfection with expression fold changes ≥ |2|. (p. 90) 
Supplementary Table S2 Identified cancer-related differentially expressed miR- 618 
targets (p. 97) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
ABBREVIATIONS 
3’UTR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3’ untranslated region  
ARE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..AU-rich element 
ATCC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . American Type Culture Collection 
cDNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Complimentary DNA 
DMEM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dulbecco's Modified Eagle's Medium 
FBS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Fetal Bovine Serum 
FOSB . . . . . . . . . . . . . . . . . . . . .FBJ murine osteosarcoma viral oncogene homolog B 
GAPDH . . . . . . . . . . . . . . . . . . . . . . . . . . Glyceraldehyde 3-phosphate dehydrogenase  
GWAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Genome Wide Association Study  
hsa-miR-618. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Human micro-RNA-618  
IGFBP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Insulin-like growth factor-binding protein   
IPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ingenuity Pathway Analysis 
JUN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jun proto-oncogene 
KH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K-homology domain 
LKB1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Liver kinase B1 
KIT . . . . . . . . . . . . . v-kit HardyZuckerman 4 feline sarcoma viral oncogene homolog 
MEX-3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Muscle excess-3 homolog (C. elegans) 
miRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Micro ribonucleic acid  
mRNP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Messenger ribonucleic protein 
Pre-miRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Preliminary micro-RNA 
PTPRO . . . . . . . . . . . . . . . . . . . . . . . . . .Protein tyrosine phosphatase, receptor type O  
qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Quantitative polymerase chain reaction 
RBP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .RNA-binding protein  
RING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Really Interesting Element 
 13 
siRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Short interfering RNA 
SNP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Single Nucleotide Polymorphism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
CHAPTER 1: INTRODUCTION  
 The field of public health is changing. With the exponential decline of the cost 
of whole-genome sequencing in tandem with explosive growth in research and 
technology, we have seen a new paradigm emerge in public health research that 
integrates population-based observations with complex data describing the 
complexities of molecular mechanisms underlying complex diseases. No longer do 
molecular research and traditional epidemiology need to remain separated. Rather, an 
integrative approach is feasible—even warranted—and is gaining tractability and 
popularity. This approach is much more powerful than a dis-integrated approach, 
bridging gaps between medicine, bench-side research, and epidemiology, thus 
providing a more relevant and 21st-century approach to studying diseases.  
For the past decade, the genome-wide association study (GWAS) has been at 
the forefront of genome-wide efforts to identify genetic variants that impact complex 
human traits, providing key insights into the underlying allelic architecture of 
complex human diseases. However, as we transition into what is commonly dubbed 
the "post-GWAS" era of cancer genomics, and genome-wide initiatives move from 
being novel to routine, it has become apparent that the main lesson learned from 
GWAS efforts is that most cancer-associated genetic variants have only minor effects 
on disease phenotype and, in total, explain only a small fraction of disease heritability. 
This is due in part to the limited scope of genetic analyses that fail to account for the 
complex interactions that occur between environmental stimuli and genetic and 
epigenetic phenomena and in part due to the stringent statistical requirements inherent 
to the GWAS. 
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1.1 Function of microRNAs 
One such epigenetic mechanism involves microRNAs (miRNAs), a group of 
noncoding RNAs that have recently been found to silence genes post-transcriptionally. 
miRNAs are small RNA molecules of 20-22 nucleotides that silence target genes by 
either degrading the target mRNA or by preventing its translation.1 Surprisingly, 
miRNAs have a large impact on genome-wide expression levels, as single miRNAs 
have been shown to regulate expression of several hundred genes.2 It is estimated that 
miRNAs control the expression of at least a third of all mRNAs in the human 
genome.3 Thus, the role of miRNAs is fundamental in cellular processes, and aberrant 
expression of these RNAs is tied to a number of diseases and many types of cancer, 
including breast, colorectal, prostate, and lung cancer.3-7 The first identified miRNAs 
in C. elegans, lin-4 and let-7 8 
Since their discovery in the early 1990s, microRNAs have been thoroughly 
investigated, and their role in gene expression has been well studied. MicroRNAs are 
small RNA molecules of 20-22 nucleotides.1 The biogenesis of miRNAs is complex 
and includes a number of proteins, including members of the Argonaute family, 
polymerase II-dependent transcription, and RNAses Drosha and Dicer.9 After 
transcription processing by the Drosha complex, the 60-110 nucleotide precursor 
miRNA, or pre-miRNA, is then exported from the nucleus and is further processed by 
Dicer and TAR RNA-binding protein 2 (TARBP2) to create the final 20-22 
nucleotide mature, double-stranded miRNA in the cytoplasm.10 Once the mature 
miRNA is formed, the antisense strand becomes incorporated into the miRNA-
containing RNA-induced silencing complex (mi-RISC) and guides the complex to its 
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target mRNA. After hybridization between the miRNA and mRNA, the mRNA is 
degraded and thus prevents gene expression. Surprisingly, miRNAs have a large 
impact on genome-wide expression levels, as a single miRNA can downregulate 
expression of several hundred genes.3 
1.2 Role of miRNAs in cancer  
 The role of aberrant miRNA expression in cancer and other diseases has been 
extensively investigated in the past 10 years. miRNAs are frequently located at fragile 
sites in the chromosome and in genomic regions that have been linked to cancer.11 
Importantly, miRNAs can have a role as either oncogenes or tumor suppressors 
(collectively termed as oncomirs).3,9,12 Oncogenic miRNAs typically target tumor 
suppressor genes, while tumor suppressive miRNAs usually repress oncogene 
expression (See Figure 1.2). Aberrant miRNA expression is often due to 
hypermethlated CpG islands proximal to the encoded miRNA.10 Notably, abnormal 
miRNA expression has been found in almost all solid tumors and hematologic 
malignancies.9,13,14 We and other groups have also identified associations between 
single nucleotide variations in miRNAs and cancer.15,16  
Due to their ability to modulate gene expression by post-translational 
repression, miRNAs that target oncogenes (tumor-suppressive miRNAs) are essential 
for maintaining stability and preventing tumorigenesis. However, it has been recently 
discovered that when these miRNAs are aberrantly downregulated, there is an 
increased risk of genomic instability, cell cycle aberrations, and possibly cancer. Thus, 
certain cancers are likely to display a profile of differentially expressed microRNAs. 
Following this discovery, several specific miRNAs have been identified that are 
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strongly downregulated in certain types of cancers. Conceivably, miRNAs could be 
introduced into the cell as miRNA “replacement therapy,” thereby artificially 
reversing the aberrant lack of presence of these regulatory RNAs (see Figure 1 for a 
conceptual summary). Indeed, a number of recent studies have successfully 
demonstrated efficacious treatment of cancers in vivo that support this “replacement 
therapy” hypothesis.  
1.3 Effects of DNA methylation in cancer 
 Gene expression is not determined solely by the DNA base sequence; it also 
depends on epigenetic phenomena, defined as gene-regulating activities that do not 
involve changes in DNA sequence whose effects may be inherited. 17 Epigenetic 
control of gene expression occurs through two primary mechanisms: DNA 
methylation (i.e., 5-methylcytosine content of DNA) and chromatin modification (i.e., 
the preservation of DNA protein complexes). Although epigenetic regulation of gene 
expression has been known and studied for decades, little disease-related work was 
done in this area until the close of the last century. Epigenetic regulation of gene 
expression is a dynamic process, and the epigenetic status of a gene can change over 
the lifetime of an organism. This ability to change and adapt in response to 
developmental cues, environmental cues, or both rests primarily on post-synthetic 
modifications either of the DNA itself (e.g., via methylation) 18 or of proteins that 
intimately associate with DNA (e.g., the acetylation, methylation, or phosphorylation 
of histones). 19 These modifications can then be interpreted by proteins (e.g., DNA 
methyltransferases and histone deacetylases) that recognize a particular modification 
and facilitate the appropriate downstream biological events.20 
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 A major focus of epigenetic research has been the identification of CpG-rich 
sequences, termed CpG islands, and the determination of methylation patterns within 
these regions in relation to disease status. The most common post-synthetic 
modification of the mammalian genome is the methylation of the 5’ position of 
cytosines in dinucleotide CpG sequences. Approximately 60–90% of all dinucleotide 
CpG sequences in the genome are methylated, while unmethylated dinucleotides are 
mainly clustered in CpG islands in gene promoters.21 Although the addition of a 
methyl group does not alter base pairing, it can impinge on protein-DNA interactions 
via the attenuation of binding affinity of sequence-specific DNA binding proteins for 
their cognate cis elements and result in changes in chromatin structure and histone 
acetylation status. 22  Normally, both the core promoter and transcription start site are 
located within the CpG island, and gene expression is completely repressed when this 
region becomes hypermethylated. As such, the predominant role of DNA methylation 
encompasses a wide range of functions, including developmental and tissue-specific 
gene transcription,23,24 imprinted gene expression,25 expression of transposable 
elements,26 chromatin organization 27 and suppression of integrated foreign DNA.28,29 
The relative plasticity of epigenetic mechanisms makes the study of epigenetics a 
powerful paradigm in the investigation of disease etiologies. In particular, epigenetics 
may offer an opportunity to further our understanding of a number of features of 
complex diseases that traditional DNA sequence–based genetics has been unable to 
explain.30 
1.4 RNA binding proteins and disease relevance 
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RNA-binding proteins (RBPs) form a class of highly evolutionarily conserved 
post-transcriptional regulators found in a variety of organisms. Nascent mRNAs 
associate with RBPs during transcription to form messenger ribonucleoprotein 
(mRNP) complexes. RBPs direct and control the localization, stability, or translation 
of their target RNAs.31 Recent studies underscore the importance of such proteins in a 
variety of physiological functions, including stem cell differentiation, embryogenesis, 
and cancer.32 Most RBPs recognize the secondary structures formed by their target 
mRNA, but are also able to recognize certain intrinsic features of RNA such as 
certain sequence motifs, the 5’ cap or the 3’ poly (A) tail. Furthermore, RBPs are 
involved in miRNA stabilization and processing, and disruption between the interplay 
between miRNA and RBPs have clear implications in cancer.33,34  
Recent high throughput techniques such as photoactivatable-ribonucleoside-
enhanced UV crosslinkning and immunoprecipitation (PAR-CLIP), iCLIP, and CLIP-
seq have identified the mRNA-bound proteome.35-37 From these advanced techniques, 
more than 800 mammalian RBPs with over 40 RNA-binding domains (RBDs) for 
recognition of secondary structures of specific sequence motifs have been 
identified.31,32 This includes RNA recognition motifs (RRMs), the K-homology (KH) 
domain, double-stranded RNA binding motif (dsRBM), the Arg-Gly-Gly (RGG) box, 
DEAD/DEAH box, and Piwi/Argonaute/Ziwi (PAZ) domains.38 KH domains are 
important motifs in RNA-binding activity, and a number of studies have elucidated 
the importance of the motif’s function in RNA binding and gene regulation.39,40 
  Many RBPs are relevant to a number of diseases, particularly in cancer. For 
example, the RBP insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is 
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upregulated in several types of cancer, and has been shown to display oncogenic 
activity through binding and stabilizing c-MYC and MK167 mRNA.41 Other 
members of the IGF2BP family such as IGF2BP2 and IGF2BP3 have been shown to 
be post-transcriptional drivers of cancer progression and can regulate important 
drivers in cancer including β-catenin, let-7 microRNA, KRAS, and MDR1.41-44   
1.5 MEX-3  
MEX-3 is a translational repressor and RNA-binding proteins originally 
discovered in C. elegans. Vertebrates have four MEX-3 analogues, and are highly 
evolutionarily conserved across species. The MEX-3 family plays an important role 
in a number of cellular functions, but most recently they have been found to play a 
central role in cell differentiation and cell renewal, and are thus of major concern to 
stem biology and cell biology.45   
Studies in C. elegans underscore the importance of MEX-3 in embryonic 
development. Mutations in Mex-3 are embryonic lethal and cause defects in the AB 
anterior blastomere descendants, particularly in the body wall muscle, thus the name 
muscle excess 3 for Mex-3.46 In oocytes, Mex-3 is uniformly distributed, but becomes 
asymmetrically overexpressed in the two anterior blastomeres at the four-cell stage.47 
MEX-3 targets PAL-1 in the PAL-1 3’UTR and prevents its translation in the anterior 
blastomeres.48,49 Thus, MEX-3 spatially represses PAL-1. PAL-1 is necessary for 
establishing the posterior blastomeres. In addition to its role in establishing the 
anterior blastomeres MEX-3 is also involved in ensuring segregation of P granules at 
the eight-cell stage.46 P granules contain maternal mRNAs and are thought to be 
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involved in determining the germline.47 Thus, this function suggests the importance 
of MEX-3 in establishing the specification of this cell lineage.  
Importantly, MEX-3 family members are highly evolutionarily conserved 
across species. Phylogenetic analysis reveals that ancestral mex-3 underwent two 
round of duplication after vertebrate lineage divergence, which accounts for the 
presence of four homologues in both mice and humans.50 MEX-3 contains two K 
homology (KH) domains that contain RNA-binding activity. The structure of the KH 
domain bound to its target RNA is shown in Figure 1.3. However, vertebrates contain 
an additional domain, perhaps a neo-functionalization that may have arisen during 
species divergence, the carboxy terminus really interesting new gene (RING) finger 
domain, which is absent in C. elegans. RING domains have been shown to mediate 
E3 ubiquitin ligase activity. Such activity has been shown in MEX-3C, which is 
responsible for degradation of human leukocyte antigen serotype A2 (HLA-A2) 
mRNA.51  
1.6 Disease relevance of MEX-3 family 
While the primary function of MEX-3 proteins in humans is unknown, recent 
evidence suggests they carry a role in cancer and other diseases, including 
hypertension, metabolic diseases, and cancer.52-54 Interestingly, MEX3A 
overexpression in an intestinal cell line lead to impaired differentiation and altered 
polarity.55 Further, MEX-3 in C. elegans represses cell-cycle inhibitor cyclin-
dependent kinase inhibitor-2 (CKI-2)56, whose human orthologues p21, p27, and p57 
contain tumor suppressive activity.45 Furthermore, silencing of MEX-3C causes 
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chromosome mis-segregation, structural abnormalities, and DNA replication stress.45 
Data from the Oncomine database (http://www.oncomine.com) strengthens the 
possible role of MEX-3 family members in cancer, as there are large amounts of data 
that suggest its overexpression in cancer compared to normal tissue.  
MEX-3D, a member of the hMEX-3 family, is expressed in somatic tissue in 
humans, contrasting with the expression profile of its analogues, which are restricted 
to the embryo and the germ line. Interestingly, the Oncomine database reveals that 
MEX-3D is highly overexpressed in a number of cancer samples compared to normal 
tissue. Yet, there is a gross lack of understanding of the role of this protein in both 
normal cell physiology and in cancer. As such, we aimed to elucidate these roles by 
with an emphasis on glioma. The success of this project would have profound 
implications both in cancer biology and in the clinical relevance of these proteins, as 
they could serve as potential biomarkers or candidates for gene therapy in breast 
cancer.   
Despite gaining recent momentum in research, there is a gross lack of 
understanding of the role of these proteins. Namely, there are four major deficits in 
MEX3 family research (adapted by Pereria et al. 201345): (1) Identification of RNA 
targets and mechanism or recognition and regulation; (2) Distinction of functional 
redundancy between MEX-3 family members; (3) Determination of interactions 
between signaling pathways and molecular processes; and (4) Analysis of 
physiological and pathological roles, especially in cancer.  
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Interestingly, the Oncomine database reveals that MEX-3D is highly 
overexpressed in a number of cancer samples compared to normal tissue. Yet, there is 
a gross lack of understanding of the role of this protein in both normal cell physiology 
and in cancer. The goal of this study was to determine the effects of MEX3D in 
glioma.  
1.7 Epidemiology and clinical characterization of glioma 
Malignant brain tumors comprise a frightening and deadly diagnosis. Little 
advances in this area have improved outcomes. An estimated 138,000 patients were 
newly diagnosed with a primary malignant brain tumor in the United States in 2010.57 
Dismally, the 5- 10- and 20- year overall survival rates for all gliomas are 54%, 45%, 
and 40%, respectively.57 The World Health Organization (WHO) classification 
system categorizes glioma into four distinct histological grades differentiated by 
increasing degrees of dedifferentiation, anaplasia, and aggressiveness.58 Grade III 
tumors include astrocytomas, oligodendroglioma, and oligoastrocytoma.58 Grade IV 
tumors, or glioblastoma, account for 82% of cases of malignant glioma and are 
defined histologically by considerable cellularity, mitotic activity, vascular 
proliferation, and necrosis.59 Sadly, the 5-year survival rate for glioblastoma is 
4.7%.60  
Malignant gliomas arise from sequential genetic alterations from intrinsic and 
environmental influences. Contrary to public perception, risk factors for glioma do 
not include exposure to cell phones.59,61,62 These studies are limited by a number of 
factors including recall bias, inconsistent measurement of cell phone usage, and 
varying cell phone technologies over time. Established risk factors for glioma are 
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limited, but include ioninizing radiation.63,64 Gliomas are most common later in life, 
especially in the sixth to eighth decade of life.59 Family history has a moderate 
influence on risk for glioma and is associated with about a 2-fold increase in risk of 
developing glioma.59 Genome-wide association studies have identified a few genes 
that are weakly associated with glioma, including 0q13.33 (RTEL), 5p15.33 (TERT), 
9p21.3 (CDKN2BAS), 7p11.2 (EGFR), 8q24.21 (CCDC26), and 11q23.3 
(PHLDB1).65,66 
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Figure 1.1 Role of miRNAs in gene expression  
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Figure 1.1 Role of miRNAs in gene expression 
miRNA silences translation of a gene through post-transcriptional targeting. First, the 
target gene is transcribed in the nucleus. Once exported into the cytoplasm, the 
miRNA binds to the target mRNA, usually in the 5’UTR region. This blocks the 
translation of the mRNA by preventing binding of translational machinery and thus 
preventing the encoded protein from being translated. It is important to note that a 
single miRNA can have up to hundreds of targets through non-specific binding.  
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Figure 1.2 Role of miRNAs in molecular carcinogenesis  
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Figure 1.2 Role of miRNAs in molecular carcinogenesis 
miRNAs can act as either oncogenes or tumor suppressor genes. Oncogenic miRNAs 
typically silence translation of tumor suppressors and the expression of these 
miRNAs remains at a relatively low level of expression in normal cells. However, if 
overexpressed, they can inhibit translation of tumor suppressors, leading to decreased 
tumor suppressor expression, and increased likelihood of carcinogenesis (a). 
Conversely, tumor suppressive miRNAs typically inhibit expression of oncogenes. 
When these miRNAs are underexpressed, they lead to overexpression of tumor 
suppressors, thus potentially leading to carcinogenesis (b).  
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Figure 1.3 Schematic of mRNA in humans and regulation of post-transcriptional 
activity 
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Figure 1.3 Schematic of mRNA in humans and regulation of post-transcriptional 
activity  
The generic structure of a eukaryotic mRNA, illustrating some post-transcriptional 
regulatory elements that affect gene expression. Abbreviations (from 5’ to 3’): UTR, 
untranslated region; m7G, 7-methyl-guanosine cap; hairpin, hairpin-like secondary 
structures; RBP, RNA-binding protein; uORF, upstream open reading frame; IRES, 
internal ribosome entry site; mRNP, messenger ribonucleoprotein; CPE, cytoplasmic 
polyadenylation element; AAUAAA, polyadenylation signal. Based on Mignone et al. 
2012.67 
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Figure 1.4 3D structure of the KH domain 
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Figure 1.4 3D structure of the KH domain 
The structure was adapted by Lewis et al. 2000.68 It shows the Nova-2 KH3-RNA 
complex. The structures highlight the dimeric assembly of the KH domains.  
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CHAPTER 2: MIR-618 DISPLAYS POSSIBLE ONCOGENIC ACTIVITY 
2.1 INTRODUCTION 
One newly identified miRNA, hsa-miR-618, is located in the chromosomal 
region 12q21.31.22 Interestingly, an increased risk for prostate cancer has been 
associated with low copy number variation with this region.69 Also, two recent studies 
have suggested a possible role of miR-618 in cancer. One study identified a single 
nucleotide polymorphism in miR-618 and found a weak, non-significant positive 
association with risk of breast cancer.15 A second recent study identified miR-618 as a 
possible biomarker for hepatocellular carcinoma among patients infected with 
Hepatitis C.16 Yet, these findings have not been supported, and the potential role of 
miR-618 in cancer remains unclear.  
In order to elucidate the role miR-618 plays in cancer, we investigated the 
differential gene expression associated with miR-618 transfection into cultured cells 
using genome-wide expression microarray analysis. After the gene expression levels 
were obtained, significantly altered transcripts were investigated for network and 
functional interrelatedness using the Ingenuity Pathway Analysis software tool. Our 
study indicates a strong correlation between miR-618 and cancer-related networks 
and genes. Three common oncogenes were upregulated—i.e. JUN, FOSB, and KIT—
while three tumor suppressor genes were downregulated as a result of the transfection, 
PTPRO, IGFBP5, and STK11 (this will henceforth referred to as LKB1). Furthermore, 
we observed a number of genes involved in hepatotoxicity and hepatocellular 
carcinoma, which supports the recent study that found an association between 
aberrant miR-618 expression and hepatocellular carcinoma. Finally, we found an 
 34 
overexpression of miR-618 in HeLa cells compared to non-cancerous End1 cervical 
cells. Overall, our results seem to implicate an oncogenic role for miR-618, and as 
such, warrant further investigation.  
 
2.2 RESULTS 
Effect of genome-wide expression levels by miR-618 transfection 
The microarray assay determined genome-wide expression in miR-618 
transfected cells compared with cells transfected with the scrambled control. 110 
identified transcripts fit our criteria for significance (Q < 0.05 and fold change ≥ |2|). 
Of these 109 transcripts, 79 showed increased expression (fold change ≥ 2), and 30 
transcripts showed decreased expression (fold change ≤ -2). The predicted secondary 
structure of pre-miR-618 is shown in Supplementary Figure S1, and an exhaustive 
list of all significantly differentially expressed genes can be found in Supplementary 
Table 1. 
 
Cancer-related networks formed by miR-618-mediated genes  
To determine which biological functions and networks may be influenced by 
miR-618, we examined the set of genes with altered expression using the Ingenuity 
Pathway Analysis software tool. We identified eight biological groups of molecules 
that contained at least ten differentially expressed transcripts. Cancer is the top 
biological-related function associated with miR-618 transfection, involving 29 
differentially expressed genes (p-value <0.05). Other identified functions include 
immunological disease (22 genes), organismal injury and abnormalities (10 genes), 
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cellular movement (16 genes), cellular development (16 genes), cellular growth and 
proliferation (20 genes), cell cycle (11 genes), and cell death (19 genes) (p-values 
<0.05). These biologically relevant functions are summarized in Table 1, and the 
cancer-related transcripts are summarized in Table 2 and detailed in 
Supplementary Table S2. Furthermore, differentially expressed transcripts were 
associated with a number of cancer-associated functions. In addition to the genes 
identified related to cancer, cell cycle, cell death, and cellular growth and 
proliferation, we also identified significant associations with tumor morphology (4 
molecules), and DNA repair (7 molecules). These cancer-related functions are 
summarized in Figure 1.  
The top network identified, “Post-translational modification, cellular 
development, cellular growth and proliferation”, consists of 11 overexpressed 
transcripts (ANG, DCN, FGFBP1, FOSB, HMGB1, JUN, KIT, KRT18, MIF, PCDH1, 
and PDGFRB) and 5 underexpressed transcripts (CBX5, IGFBP5, PDGFRA, PTPRO, 
and LKB1). Importantly, several of these upregulated genes, namely FOSB, JUN, and 
KIT, are well known oncogenes. Known functions and respective fold changes of 
genes in this network are summarized in Table 2. Figure 2 presents the peptides 
encoded by these genes in their respective locations of function in the cytoplasm, 
nucleus, cell membrane, or extracellular space. The second top network identified 
was “Cellular movement, cell death and survival, and cell cycle.” The software 
identified eight overexpressed transcripts (SGK3, EDN2, HUWE1, IFI27, MAPK4, 
MIF, NUDCD2, and TM4SF1) and two underexpressed transcripts (C1QTNF5 and 
CLDN5). Supplementary Figure S2 presents a graphical representation related to 
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this network. All microarray expression data have been uploaded to the Gene 
Expression Omnibus (GEO) database, and can be accessed via their website 
(http://www.ncbi.nlm.nih.gov/geo/; accession # pending). 
 
Overexpression of miR-618 in Hela cells 
 In order to determine if miR-618 is overexpressed in cancer compared to 
normal tissue, we performed an expression analysis in miR-618 non-transfected HeLa 
cervical cancer cells relative to End1 cervical cells. The expression analysis in HeLa 
cells revealed an overexpression of miR-618 by 2.68-fold relative to End1 cells 
(Figure 3).  
  
2.3 DISCUSSION 
 The importance of miRNAs in regulating and maintaining a variety of cellular 
functions is widely known and studied. Certain miRNAs carry the potential for either 
oncogenic or tumor suppressive activity, and can regulate cancer-related gene 
networks. After analyzing the effects of miR-618 transfection on genome-wide 
expression levels in HeLa cells, we report here the oncogenic role of miR-618 and its 
regulatory impact on cancer-related gene networks. miR-618 is located in the 
12q21.31 region, and interestingly, an increased risk for prostate cancer has been 
associated with low copy number variation in this region.69 The gene MGAT4C also 
maps to 12q21.31, and its copy number variation has been associated with prostate  
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Recently, our group has described the effects of miR-618 in non-Hodgkin 
lymphoma.70 A total of 128 miR-618 targets were identified that were enriched for 
genes that have functional roles in lymphoma-relevant pathways. The study also 
revealed a significant association between rs2682818 G>T in the miR-618 and 
follicular lymphoma (FL) (OR: 1.65, 95% CI: 1.05-2.60). In vitro analysis of 
rs2682818 functional impact revealed that the variant T allele resulted in reduced 
levels of mature miR-618, which in turn may lead to deregulation of miR-618-
controlled pathways relevant to follicular lymphoma. 
We identified three overexpressed oncogenes from the miR-618 transfection. 
JUN, FOSB, and KIT are commonly studied oncogenes and were upregulated by fold 
changes of 2.79, 3.62, and 2.20, respectively (Q-values <0.05). These genes all 
belong to the top identified network “Post-translational modification, cellular 
development, cellular growth, and proliferation.” Notably,  FosB has been 
demonstrated to lead to increased cell invasion in MCF7 cells.71 Together, FosB and 
Jun form a heterodimer and are both highly overexpressed in a variety of cancers.72 
The Jun/FosB complex is essential for regulating a number of cancer-related 
functions, including invasion and metastasis, cell proliferation, cell differentiation, 
angiogenesis, and cell survival.73 Further, the c-Kit receptor, a transmembrane protein, 
is a notable member of the type III receptor tyrosine kinase family and also regulates 
similar biological functions as Jun/FosB, including cell proliferation, cell 
differentiation, cell development, and cell migration.74 Overexpression or abnormal 
regulation of c-Kit has been strongly linked to cancer.75 Thus, miR-618 carries 
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important oncogenic activity by upregulating these oncogenes involved in 
mechanisms central to cancer and tumorigenesis. 
PTPRO, IGFBP5, and LKB1 were significantly underexpressed tumor 
suppressors following miR-618 transfection with fold changes of -2.07, -2.02, and -
2.38, respectively (Q-values <0.05). PTPRO encodes a protein tyrosine phostphatase 
receptor that is involved in proper entry into the G1 phase and regulates apoptotic 
pathways.76  Loss-of-function of this receptor is highly associated with cancer.76 
IGFBP5, which encodes an insulin-like growth factor binding protein, is another 
important protein in cancer that is essential in inhibiting mitogenesis, cell 
differentiation, and in preventing metastasis.77,78 Aberrant IGFBP5 expression has 
been documented in a number of cancers. LKB1 encodes an important 
serine/threonine kinase-activating kinase in which loss-of-function leads to Peutz-
Jehers syndrome and sporadic cancers such as lung and cervical cancer.79 LKB1 plays 
a role in phosphorylation cascades that regulate essential cellular processes such as 
cytoskeleton organization, cell proliferation, and metabolism.79  This strengthens 
support of the putative role of miR-618 in cancer, as the loss of tumor suppressor 
genes and overexpression of oncogenes is a common phenotype in nearly all cancers.  
Importantly, a recent study found a significant association between 
upregulated miR-618 expression and hepatocellular carcinoma (HCC) among 
Egyptian patients infected with Hepatitis C virus (HCV),80 identifying miR-618 as a 
potential risk biomarker for HCC. Interestingly, our IPA analysis found an 
upregulated gene that is associated with hepatocellular carcinoma, IL22RA, due to 
miR-618 transfection. IL22RA is directly associated with carcinoma and carcinoma in 
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situ. More importantly, IL22RA is found within the same interaction network as IL22, 
which is associated with hepatocellular carcinoma and liver tumorigenesis, 
proliferation, hyperplasia, and hypertrophy (all p-values <0.05). Furthermore, we 
identified seven molecules associated with hepatotoxicity and hepatocellular 
carcinoma that were differentially expressed: TM4SF1, KIT, PDGFRB, HUWE1, 
HMGB1, PTPRO, PDGFRA, and MATN3 (p-value = 5.72 x 10-3; see Supplementary 
Table S1 for more information). PTPRO  has been associated with hepatocellular 
carcinoma progression when underexpressed, and exhibited a -2.07-fold change in 
expression (Q<0.05) following miR-618 transfection.81 Thus, taken in the context of 
miR-618 as a biomarker for hepatocellular carcinoma, our analysis implicates miR-
618 as a potential upstream effector of hepatocellular carcinogenesis via its 
interactions with genes relevant to HCC proliferative and hepatotoxicity pathways. 
Interestingly, an A>C single nucleotide polymorphism (SNP), rs2682818, has 
been identified in miR-618 that may be involved in cancer. According to the NCBI 
SNP database, the hsa-miR-618 SNP variant (C to A) has been most commonly found 
among Japanese and African American individuals, and least common among 
Caucasians (A genotype frequency 0.320, 0.320, and 0.170, respectively).82 A study 
by Zhang et al. recently investigated the role of this SNP in miR-618 in breast cancer 
among Chinese females, but found no significant association.15 However, the study 
was limited due to its small sample size, thus further investigation is necessary to 
explore the potential role of the SNP in miR-618 in tumorigenesis in breast cancer 
and in other cancers. A study in 2010 by Cicatiello et al. identified miR-618 as a 
target of 17β-estradiol in estrogen-responsive breast cancer MCF-7 breast cancer 
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cells.83 The findings both associate miR-618 in breast cancer and demonstrate that 
miR-618 is responsive to estrogen control of target gene activity. These studies 
support our findings by providing a possible role of aberrant miR-618 expression in 
breast cancer specifically.   
 As with all in vitro studies, there are several limitations in this study. As the 
miR-618 transfection was conducted in HeLa cells, the findings are limited to genes 
with detectable expression levels in this cell line. HeLa cells have a gene expression 
profile that differs from those of other cell lines, and, as such, it is likely that some 
observed expression changes may be HeLa-specific. Further, since we determined 
following the transfection and network analysis that miR-618 is upregulated in HeLa 
cells compared to End1 cells, the results may have been more meaningful in a cell 
line in which miR-618 was not overexpressed. Nevertheless, our findings indicate a 
strong potential role for miR-618 in cancer. In combination with the previous 
suggestion of miR-618 as a potential biomarker for hepatocellular carcinoma, 
evidence strongly supports a possible role of this miRNA in hepatocellular carcinoma, 
liver cancer, and other diseases. A number of future studies are warranted based on 
our results, including an expansion of this analysis to other cell lines, and an 
investigation of the role of this miR-618 in clinical samples. 
As previous evidence regarding the role of the novel miRNA miR-618 in 
cancer remains unclear, we present evidence that miR-618 may serve an important 
role in cancer, finding that it affects the expression of key oncogenes and tumor 
suppressors and that it operates in cancer-related pathways. Our observations of miR-
618 overexpression in cancer cells support an oncogenic role of miR-618. Taken 
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together with our findings of overexpressed oncogenes and underexpressed tumor 
suppressor genes following miR-618 transfection, miR-618 is a likely oncomir. Our 
data indicate that when overexpressed, miR-618 may carry an oncogenic role by 
modulating pathways leading to increased cell growth, cell migration, cell invasion, 
and cell proliferation. Notably, our findings suggest a role for miR-618 in 
hepatocellular carcinoma, as a number of genes associated with hepatocellular 
carcinoma and hepatotoxicity were dysregulated as a result of the miR-618 
transfection. Further in vitro and in vivo studies are warranted to validate and 
elucidate the association between miR-618 and cancer and to determine the clinical  
relevance of miR-618 as a possible biomarker in cancer.  
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Table 2.1 Top biological functions of differentially expressed target genes of miR-
618 
Name No. of molecules P-valuea 
Cancer 29 8.61 x 10-7 
Immunological disease 22 8.61 x 10-7 
Organismal injury and abnormalities 10 8.61 x 10-7 
Cellular movement 16 2.95 x 10-4 
Cellular development 16 3.89 x 10-2 
Cellular growth/proliferation  20 3.89 x 10-4 
Cell cycle 11 1.55 x 10-3 
Cell death 19 2.04 x 10-3 
`a P-values represent the pooled value of the target genes and were calculated with the 
Fisher t-test.  
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Table 2.2 Identified cancer-related differentially expressed miR-618 targets 
Gene name  Expression fold 
changesa 
Gene name Expression 
fold changes 
ANG 2.25 IL22RA1 2.52 
ANXA8L2 2.19 JUN 2.79 
BIK 2.66 KCNE4 2.75 
C8ORF8/SGK1 2.17 KIT 2.20 
CDH7 2.26 KRT18 2.99 
CLDN5 -2.47 MAFA -2.02 
DCN 2.35 MATN3 -2.70 
DESI2 2.22 MIF 2.01 
FGFBP1 2.03 MX1 2.04 
FOSB 3.62 PDGFRA -2.10 
HMGB1 2.04 PDGFRB 2.04 
HUWE1 2.04 RNASE4 2.01 
IFI27 2.14 STK11/LKB1 -2.38 
IGFBP5 -2.02 TM4SF1 3.16 
a All fold changes have a Q value of <0.05.  
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Figure 2.1 Cancer-related functions of selected differentially expressed genes 
 
 
 
 
 
 
 
0 
1 
2 
3 
4 
5 
6 
7 
0 
5 
10 
15 
20 
25 
30 
-lo
g(
p 
va
lu
e)
 
N
o.
 m
ol
ec
ul
es
 
Function 
No. 
Molecules 
-log(p value) 
 45 
Figure 2.1: Cancer-related functions of differentially expressed transcripts. 
Seven biological functions associated with cancer were identified using the IPA 
software: cancer, cell growth and proliferation, cell cycle, cell death, tumor 
morphology, gene expression, and DNA repair. The left y-axis indicates the number 
of identified molecules for each function represented by the bars. The right y-axis 
indicates the –log of the pooled p-values for each function, represented by the marked 
line. The statistical significance threshold of –log(p=0.05) is given by the straight line.  
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Figure 2.2 Differentially expressed genes in the “Post-translation modification, 
cellular development, and cellular growth and proliferation” network  
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Figure 2.2 Differentially expressed genes in the “Post-translational modification, 
cellular development, and cellular growth and proliferation” network 
Network of differentially expressed transcripts following miR-618 transfection under 
the “post-translational modification, cellular development, and cellular growth and 
proliferation” network. This network was identified by the Ingenuity Pathway 
Analysis software as significantly associated with the set of transcripts with altered 
expression following the introduction of the miR-618 mimic (pooled p-value = 8.61 x 
10-7 and FDR ≥ |2|). Overexpressed transcripts are indicated in red, and 
underexpressed transcripts are indicated in green. Transcripts indicate the relative 
location by either in the nucleus, cytoplasm, cell membrane, or extracellular matrix.  
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Figure 2.3 miR-618 is overexpressed in HeLa cells relative to End1 cells.  
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Figure 2.3 miR-618 is overexpressed in HeLa cells relative to End1 cells 
qPCR results of quantifying miR-618 levels in HeLa cells relative to End1 cells 
reveals a 2.68 fold change in cancer vs. non-cancer cells. Expression levels were 
quantified using the 2-∆∆Ct method with normalization to the stably expressed ncRNA 
U6B, where ∆∆Ct = (Ct:miR-618_HeLa – Ct:U6B_HeLa) – (Ct:LmiR-618_End1 – Ct:U6B_End1). Error 
bars represent the standard deviation of the CT values.  
cancer among Caucasian males (OR = 4.8, p = 2.6 x 10-3), thus highlighting the 
importance of this genetic region in cancer.69  
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CHAPTER 3: MEX3D IS OVEREXPRESSED ACROSS CANCER TYPES 
3.1: INTRODUCTION 
RNA-binding proteins (RBPs) form a class of highly evolutionarily conserved 
post-transcriptional regulators found in a variety of organisms. Recent studies 
underscore the importance of such proteins in a variety of physiological functions, 
including stem cell differentiation, embryogenesis, and cancer.32 MEX-3 is a 
translational repressor and RNA-binding proteins originally discovered in C. elegans. 
Vertebrates have four MEX-3 analogues, and are highly evolutionarily conserved 
across species. The MEX-3 family plays an important role in a number of cellular 
functions, but most recently they have been found to play a central role in cell 
differentiation and cell renewal, and are thus of major concern to stem biology and 
cell biology.45  
Importantly, MEX-3 family members are highly evolutionarily conserved 
throughout species. Phylogenetic analysis reveals that ancestral mex-3 underwent two 
round of duplication after vertebrate lineage divergence, which accounts for the 
presence of four homologues in both mice and humans.50 MEX-3 contains two K 
homology (KH) domains that contain RNA-binding activity. However, vertebrates 
contain an additional domain, perhaps a neo-functionalization that may have arisen 
during species divergence, the carboxy terminus really interesting new gene (RING) 
finger domain, which is absent in C. elegans. RING domains have been shown to 
mediate E3 ubiquitin ligase activity. Such activity has been shown in MEX-3C, which 
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is responsible for degradation of human leukocyte antigen serotype A2 (HLA-A2) 
mRNA.51  
While the primary function of MEX-3 proteins in humans is unknown, recent 
evidence suggests they carry a role in cancer and other diseases, including 
hypertension, metabolic diseases, and cancer.52-54 Interestingly, MEX3A 
overexpression in an intestinal cell line lead to impaired differentiation and altered 
polarity.55 Further, MEX-3 in C. elegans represses cell-cycle inhibitor cyclin-
dependent kinase inhibitor-2 (CKI-2)56, whose human orthologues p21, p27, and p57 
contain tumor suppressive activity.45 Furthermore, silencing of MEX-3C causes 
chromosome mis-segregation, structural abnormalities, and DNA replication stress.45 
However, the overall function of MEX3 proteins in humans is largely unknown, 
especially in the context of cancer development. As such, this study aimed to profile 
the expression of MEX3D as well as the other members of the MEX3 family, 
MEX3A-C, in a number of tumors compared to normal tissue in order to guide 
molecular studies presented in Chapter 4.  
Case-control studies deposited in the Oncomine database 
(http://www.oncomine.com) reveal that MEX3 family members are highly 
overexpressed in many types of cancer. In particular, we show here that MEX3D is 
overexpressed in melanoma, sarcoma, glioma, pancreatic cancer, cervical cancer, 
colorectal cancer, lymphoma, gastric cancer, and oral cancer. These findings are 
crucial, as they point to clear evidence that MEX3 family members play a role in 
tumor development. Future studies are needed to understand the mechanistic role of 
the proteins.   
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3.2 RESULTS 
 
MEX3D is overexpressed in many types of cancer  
According to the Oncomine database, MEX3D is overexpressed in five types 
of gastrointestinal cancers. In gastric cancer, there was a fold change of 2.52 (p = 
2.03x10-8) in MEX3D measured in 31 paired gastric carcinoma and adjacent normal 
gastric mucosa. The results are from a human genome U133 Plus 2.0 Array.84 70 
colorectal carcinoma and 12 normal colon samples were analyzed with the U133 Plus 
2.0 Array. There was a 2.59-fold change in colorectal cancer vs. normal samples (p = 
2.04x10-8).85 In pancreatic cancer, 36 pancreatic carcinoma and 16 paired normal 
samples were analyzed with the Human Genome Plus 2.0 Array. The analysis 
revealed that MEX3D is 2.88-fold overexpressed in pancreatic cancer vs. normal 
tissue (p = 1.89x10-9).86 Another study looked at 7 rectal adenoma samples and 25 
colon adenoma samples matched with 32 normal samples using the U133 Plus 2.0 
Array. The study found that MEX3D is 2.76-fold overexpressed in rectal adenoma vs. 
normal tissue (p = 9.33x10-6) and 2.09-fold overexpressed in colon adenoma vs. 
normal tissue (p = 5.76 x 10-11).87  
MEX3D was also overexpressed in skin cancer. The gene expression analysis 
in melanoma included 45 cutaneous melanoma samples, 18 benign melanocytic skin 
samples, and 7 normal skin samples analyzed with the U133 Plus 2.0 Array. The 
analysis revealed that MEX3D is overexpressed 2.42-fold in benign melanoma vs. 
normal skin (p = 2.58x10-6), and 4.41 in cutaneous melanoma vs. normal skin (p = 
6.96x10-9).88  
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The Oncomine database also reveals that MEX3D is overexpressed in at least 
two reproductive cancers. In prostate adenocarcinoma, using 69 prostate tumor 
samples, 18 adjacent normal prostate samples, and 2 pooled normal prostate samples 
with the U133 Plus 2.0 Array, MEX3D was found to be overexpressed in prostate 
tumor vs. normal tissue by 2.10-fold (p = 9.70x10-4).89 In cervical cancer, 20 cervical 
cancers were used with 8 cervical normal samples using the U133 Plus 2.0 Array. The 
study found MEX3D was overexpressed in cervical cancer vs. normal tissue by 2.80-
fold (p = 2.43x10-7).   
 Five types of sarcomas showed overexpression of MEX3D compared to 
normal tissue. In a study of 149 soft tissue sarcomas compared to 9 normal adipose 
tissue specimens, MEX3D was overexpressed 3.11-fold in pleomorphic liposarcoma 
vs. normal was (p = 5.51x10-8), 2.99-fold in myxofibrosarcoma vs. normal (p = 
2.82x10-10), 2.33-fold overexpressed in dedifferentiated liposarcoma vs. normal (p = 
4.28x10-8), and 2.73 in myxoid/round cell liposarcoma vs. normal tissue (p = 9.35x10-
8).90  In a separate study of 39 sarcoma samples and 15 normal tissue samples using 
the Human Genome U133A Array, MEX3D was overexpressed by 3.02-fold in 
fibrosarcoma vs. normal tissue (p = 5.48x10-6).91  
 A few other types of cancer also exhibited overexpression of MEX3D 
compared to normal tissue. Tongue cancer, a form of oral cancer, exhibits a 2.12-fold 
overexpression compared to normal tissues (p = 2.11x10-4).92 The study used 42 head 
and neck cancers compared to 14 head and neck normal samples on the Human 
Genome U133 Plus 2.0 Array.  MEX3D was also 2.84-fold overexpressed in germinal 
center B-cell-like diffuse large B-cell lymphoma vs. normal (p = 4.85x10-5), 2.37-
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fold overexpressed in activated B-cell-like diffuse large B-cell lymphoma vs. normal 
(p = 1.45x10-8), and 2.35-fold overexpressed in diffuse large B-cell lymphoma vs. 
normal (p = 1.57x10-12).93 A total of 73 diffuse large B-cell lymphoma samples and 
20 normal B-lymphocytes were analyzed using the Human Genome U133 Plus 2.0 
Array. Lastly, in a study of 547 glioblastoma samples compared to 10 normal brain 
samples, MEX3D was found to be 3.00-fold overexpressed in glioblastoma vs. normal 
tissue (p = 8.65x10-9).94 These data are summarized in Figure 3.1 and Figure 3.2. 
 
MEX3A-C are also overexpressed in many types of cancer 
 We also examined the expression levels of the other members of the MEX3 
family, MEX3A-C. We found that these three genes displayed an expression profile 
similar to that as MEX3D. We found that MEX3A was overexpressed in breast 
cancer, melanoma, colorectal cancer, lung cancer, glioma, ovarian cancer, uterine 
cancer, and prostate cancer. Notably, MEX3A is 19.6-fold overexpressed in basal cell 
carcinoma compared to normal skin tissue (p = 1.47 x 10-7).  
 We found that MEX3B is overexpressed in breast cancer, uterine cancer, lung 
cancer, and leukemia compared to normal tissue. Lastly, we examined the expression 
profile of MEX3C in cancer compared to normal tissue, and found overexpression in 
cervical cancer, glioblastoma, esophageal cancer, oral cancer, leukemia, sarcoma, and 
gastric cancer. The cutoff values of p-value < 1.0 x 10-4 and fold-change > |2.0| were 
used to search the Oncomine database.  
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3.3 DISCUSSION 
 
Human Mex-3A proteins, including hMex-3A, -3B, -3C and -3D, are located 
on distinct chromosomes at 1q22, 15q25.2, 18q21.1 and 19p13.3, respectively (9). All 
the four proteins contain two highly conserved KH domains specifically for RNA 
binding and a RING finger domain in their carboxy- terminal region probably 
involved in mediating protein-protein interactions (15-17). The similarity in structure 
of the hMex-3 proteins implies that they may share certain similar biological 
functions. In this study, we investigated the expression profiles of the MEX3 family 
proteins in cancer compared to normal tissue.  The data demonstrated that MEX3 
family members are overexpressed in a broad range of types of cancer. Notably, 
MEX3B is nearly 20-rfold overexpressed in basal cell carcinoma compared to normal 
skin tissue. Furthermore, we found that MEX3D is overexpressed across a broad 
range of cancers, including melanoma, sarcoma, glioma, pancreatic cancer, cervical 
cancer, colorectal cancer, lymphoma, gastric cancer, and oral cancer.  
Interestingly, one study associated the closely related gene MEX3A with 
increased cell proliferation and migration in human gastric cancer cells.95 However, 
the literature sheds little light otherwise on the role of the proteins in human and 
especially their relation to disease development. This study is the first to describe 
MEX3A-D expression in a variety of tumors as displaying possible oncogenic activity. 
Few studies have looked at this gene family, and none have yet associated MEX3D 
with cancer. The finding that MEX3D is overexpressed in many types of cancer is 
alarming and warrants further investigation. These findings are crucial, as they point 
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to clear evidence that MEX3 family members play a role in tumor development. 
Future studies are needed to understand the mechanistic role of the proteins.   
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Figure  3.1 Overexpression of MEX3D in tumors 
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Figure  3.1 Overexpression of MEX3D in tumors 
Using fold-change cutoff of > | 2.0 | and p-value cutoff of 1x10-4, the Oncomine 
database was searched for cancer vs. normal expression data for MEX3D. The search 
yielded studies in which MEX3D was only overexpressed.  
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Figure 3.2 MEX3A-C are also overexpressed across tumor types 
A.  
 
 
 
 
 
 
 
 
B.  
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Figure 3.2 MEX3A-C are also overexpressed across tumor types 
Using fold-change cutoff of > | 2.0 | and p-value cutoff of 1x10-4, the Oncomine 
database was searched for cancer vs. normal expression data for MEX3A (A), MEX3B 
(B), and MEX3C (C). The search yielded studies in which MEX3A-C were only 
overexpressed.  
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Table 3.1 Expression profiles of MEX3A-D in cancer vs. normal tissue 
Cancer Expression 
vs. normal 
Cancer Expression vs. 
normal 
MEX3A 
Breast 2.09 
Brain-
Oligodendroglioma 3.53 
Breast 3.85 Brain-astrocytoma 3.50 
Melanoma-Basal Cell  19.57 Brain-Glioblastoma 3.01 
Melanoma-Cutaneous 2.64 
Brain-diffuse 
astrocytoma 2.35 
Colorectal 3.18 Ovarian-Endometriod 2.65 
Rectal 5.38 Ovarian-Serous 2.03 
Colon 4.89 Uterine 2.26 
Lung-large cell  3.53 Prostate 2.20 
MEX3B 
Breast 2.17 Lung 2.48 
Uterine 2.91 Leukemia 2.41 
MEX3C  
Cervical 2.57 Mouth 3.23 
Brain-glioblastoma 2.59 Sarcoma-synovial 2.90 
Brain-glioblastoma 3.42 Sarcoma-limpsarcoma 2.17 
Brain-glioblastoma 2.05 Leukemia 2.58 
Brain-
oligodenroglioma 2.56 Gastric 2.25 
Esophagus 3.27   
MEX3D 
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Lymphoma 2.84 Sarcoma-fibrosarcoma 3.02 
Cervical 2.80 Sarcoma-synovial 2.73 
Melanoma-Cutaneous 4.41 Brain-glioblastoma 3.05 
Melaonma-Benign 2.42 Pancreas 2.27 
Renal 4.31 Tongue 2.12 
Sarcoma-liposarcoma 3.11 Colorectal 2.59 
Sarcoma-
myxofibrosarcoma 2.99 Rectal Adenoma 2.76 
Sarcoma-myxoid 2.73 Colon 2.09 
Sarcoma-
fibrosarcoma 3.02 Gastric 2.52 
Sarcoma-synovial 2.73 Prostate 2.10 
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CHAPTER 4: MEX3D IS AN ONCOGENE IN GLIOMA 
4.1 INTRODUCTION 
RNA-binding proteins (RBPs) form a class of highly evolutionarily conserved 
post-transcriptional regulators found in a variety of organisms. Recent studies 
underscore the importance of such proteins in a variety of physiological functions, 
including stem cell differentiation, embryogenesis, and cancer.32 MEX-3 is a 
translational repressor and RNA-binding proteins originally discovered in C. elegans. 
Vertebrates have four MEX-3 analogues, and are highly evolutionarily conserved 
across species. The MEX-3 family plays an important role in a number of cellular 
functions, but most recently they have been found to play a central role in cell 
differentiation and cell renewal, and are thus of major concern to stem biology and 
cell biology.45  
Importantly, MEX-3 family members are highly evolutionarily conserved 
throughout species. Phylogenetic analysis reveals that ancestral mex-3 underwent two 
round of duplication after vertebrate lineage divergence, which accounts for the 
presence of four homologues in both mice and humans.50 MEX-3 contains two K 
homology (KH) domains that contain RNA-binding activity. However, vertebrates 
contain an additional domain, perhaps a neo-functionalization that may have arisen 
during species divergence, the carboxy terminus really interesting new gene (RING) 
finger domain, which is absent in C. elegans. RING domains have been shown to 
mediate E3 ubiquitin ligase activity. Such activity has been shown in MEX-3C, which 
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is responsible for degradation of human leukocyte antigen serotype A2 (HLA-A2) 
mRNA.51  
While the primary function of MEX-3 proteins in humans is unknown, recent 
evidence suggests they carry a role in cancer and other diseases, including 
hypertension, metabolic diseases, and cancer.52-54 Interestingly, MEX3A 
overexpression in an intestinal cell line lead to impaired differentiation and altered 
polarity.55 Further, MEX-3 in C. elegans represses cell-cycle inhibitor cyclin-
dependent kinase inhibitor-2 (CKI-2)56, whose human orthologues p21, p27, and p57 
contain tumor suppressive activity.45 Furthermore, silencing of MEX-3C causes 
chromosome mis-segregation, structural abnormalities, and DNA replication stress.45 
Data from the Oncomine database (http://www.oncomine.com) strengthens the 
possible role of MEX-3 family members in cancer, as there are large amounts of data 
that suggest its overexpression in cancer compared to normal tissue.  
MEX-3D, a member of the hMEX-3 family, is expressed in somatic tissue in 
humans, contrasting with the expression profile of its analogues, which are restricted 
to the embryo and the germ line. Interestingly, the Oncomine database reveals that 
MEX-3D is highly overexpressed in a number of cancer samples compared to normal 
tissue. Yet, there is a gross lack of understanding of the role of this protein in both 
normal cell physiology and in cancer. The goal of this study was to determine the 
effects of MEX3D in glioma. We found that MEX3D is 3.00-fold overexpressed in 
glioma tissue compared to normal brain tissue. Kaplan-Meier analysis reveals that 
overexpression of MEX3D also leads to poor survival in glioma patients. Furthermore, 
we found that MEX3D leads to increased cell proliferation in A172 glioma cells. 
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Concurrently, MEX3D also leads to decreased cell invasion in both A172 and U87 
glioma cells. This study is the first to report the effect of MEX3D in cancer, and 
describes MEX3D as a potential oncogene in glioma. Further studies are warranted to 
examine the mechanistic role of MEX3D in gene regulation and in tumorigenesis.  
 
4.2 RESULTS 
MEX3D is overexpressed in glioma and leads to poor survivals.  
In order to determine the clinical relevance of MEX3D in glioma, we searched the 
Oncomine database for expression data in glioma compared to normal tissue. MEX3D is 
highly overexpressed in glioblastoma. In a study of 547 glioblastoma samples compared to 10 
normal brain samples, MEX3D was found to be 3.00-fold overexpressed in glioblastoma vs. 
normal tissue (p = 8.65x10-9) (Figure 4.1).94 We also examined the effects of MEX3D 
overexpression on overall survival in glioma patients. MEX3D expression data from n=273 
glioma patients were analyzed using the Human Genome U133 Plus 2.0 Array. The Kaplan-
Meier curve was calculated using a median-cutoff expression of 64.1 and two curves were 
calculated: a high group (n=143) with MEX3D expression greater than the median 64.1 
MEX3D expression value, and a low group (n=130) with MEX3D expression lower than the 
median 64.1 expression value. After correcting for multiple comparisons using the Bonferoni 
method, there was a statistically significant difference between the high- and low-MEX3D 
expression profile groups (p = 6.2 x 10-3).   
 
Differential methylation in MEX3D 
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 In order to understand the mechanism underlying the change in gene 
expression in cancer, we searched for evidence of differential methylation in MEX3D 
in glioma samples. We tested the methylation status of twelve matched glioma and 
normal samples. The normal tissues came from the same patient and were adjacent 
normal tissue to the tumor site. The analysis revealed that three CpG sites showed 
significant differential methylation (p<0.05) between tumor and normal tissue. One 
site in the body of MEX3D showed hypermethylation of 24% (Δβ=0.2477, p=3.4x10-
4) in tumor vs. normal tissue. Concurrently, a second site in the body of MEX3D was 
hypomethlyated in tumor vs. normal tissue by 15.4%  (Δβ= -0.154, p=0.001). A third 
location in MEX3D in the 3’UTR was found to be hypomethylated by 9.5% (Δβ= -
0.095, p=0.041). 
 
MEX3D leads to increased cell proliferation in A172 glioma cells  
 As unregulated cell proliferation is a clear hallmark of cancer, we tested 
whether knockdown of MEX3D has an effect on cell proliferation in vitro using RNA 
interference against MEX3D in A172 glioma cells. As shown in Figure 4, the 
chemically synthesized siRNA exhibited an efficient knockdown of MEX3D relative 
to the siRNA control. There was approximately a 10-fold reduction in expression of 
the knockdown compared to the control measured by qPCR. Remarkably, cell 
proliferation assays showed that si-RNA knockdown of MEX3D leads to significant 
decrease in cell proliferation in A172 glioma cells after five days compared to the 
negative control si-RNA transfected cells (p <0.001) (Figure 4.2). The negative 
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control exhibited normal cell growth, whereas the knockdown showed linear growth 
at best from days 1-4.  
MEX3D leads to decreased cell invasion in vitro  
 In order to test the effects of MEX3D on another hallmark of cancer, cell 
invasion, we performed a cell invasion assay. MEX3D was knocked down in A172 
glioma cells using si-RNA and U87 cells and compared to negative control si-RNA. 
Unexpectedly, knockdown of MEX3D led to significant increases in cell invasion, 
suggesting that MEX3D normally suppresses cell invasion. The relative fold increase 
in MEX3D knockdown compared to the negative control in A172 cells was 4.80 (p = 
0.003), and in U87 cells was 2.58 (p = 1.67 x 10-5) (Figure 4.5).  
4.3 DISCUSSION 
Human Mex3 proteins, including hMex3A, -3B, -3C and -3D, are located on 
distinct chromosomes at 1q22, 15q25.2, 18q21.1 and 19p13.3, respectively (9). All 
the four proteins contain two highly conserved KH domains specifically for RNA 
binding and a RING finger domain in their carboxy- terminal region probably 
involved in mediating protein-protein interactions (15-17). The similarity in structure 
of the MEX3 proteins implies that they may share certain similar biological functions. 
In the present study, one of the four proteins, MEX3D, was selected to investigate its 
function in glioma cancer development and progression for the first time. The final 
data demonstrated that a reduction in the MEX3D expression level led to a 
suppression of cell growth. Furthermore, the silencing of MEX3D also resulted in a 
increase in the invasion ability of gastric cancer cells. These findings shed light on the 
role of MEX3 RNA-binding proteins, particularly for MEX3D in tumorigenesis. 
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In recent years, RNA interference has been employed as a mature and 
powerful strategy for exploring gene functions by downregulating the expression of 
targeted genes. We applied this technique to specifically knockdown MEX3D in 
A172 cells and in U87 cells. We found that MEX3D appears to promote cell 
proliferation while limiting tumor invasion. Futhermore, we found that MEX3D is 
overexpressed in glioma, and that overexpression of MEX3D in glioma patients leads 
to poorer rates of survival.  
While it is well known that methylation is an important epigenetic effect and 
alters gene expression, the results of this study are inconclusive and cannot be 
interpreted. Several reasons explain this. First, the quality of the samples was 
compromised. The samples were stored in formalin fixed paraffin for a long period of 
time, thus contaminating the samples and degrading them. This was evidenced by 
heavy background noise in the data set. Further, a small sample size (n=12) limited 
the power of the study. The methylation of MEX3D is an important effect that 
warrants closer investigation and a bigger sample size.  
The fact that MEX3D appears to promote cell proliferation while limiting 
tumor invasion is somewhat paradoxical. However, the evidence we present of the 
high level of over-expression of MEX3D as well as the poorer tumor survival in 
glioma patients with high expression of MEX3D indicates that this protein plays a 
major role in tumor development, especially in the context of glioma. Thus, we 
conclude that MEX3D is a potential oncogene.  
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In conclusion, our present study is the first to show that the knockdown of 
hMex-3A using RNA interference can effec- tively inhibit cell proliferation and 
migration in gastric cancer cells. These results further indicate that hMex-3A may 
serve as a potential target for the therapy of gastric cancer, although additional studies 
in vivo are necessary. 
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Figure 4.1 MEX3D is overexpressed in glioma and leads to poor survival in 
glioma patients 
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Figure 4.1 MEX3D is overexpressed in glioma and leads to poor survival in 
glioma patients  
Oncomine database reveals that MEX3D is 3.00-fold overexpressed in glioma tumors 
vs. normal brain tissue (p = 8.65 x 10-9) (A). Using median-expression cutoffs in the 
Kaplan Meier survival analysis, overexpression of MEX3D is associated with poorer 
survival in all glioma patients (B). The red, top line represents lower expression of 
MEX3D, whereas the bottom blue line represents higher expression of MEX3D. 
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FIGURE 4.2 Methylation of CpG sites in MEX3D in glioma vs. normal samples 
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Figure 4.2 Methylation of CpG sites in MEX3D in glioma vs. normal samples 
Analysis of methylation status of MEX3D reveals that one site in the body of MEX3D 
showed hypermethylation of 24% (Δβ=0.2477, p=3.4x10-4) in tumor vs. normal tissue. 
Concurrently, a second site in the body of MEX3D was hypomethlyated in tumor vs. 
normal tissue by 15.4%  (Δβ= -0.154, p=0.001). A third location in MEX3D in the 
3’UTR was found to be hypomethylated by 9.5% (Δβ= -0.095, p=0.041). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
 
Figure 4.3 Knockdown of MEX3D in A172 cells  
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FIGURE 4.3 Knockdown of MEX3D in A172 cells 
si-RNA knockdown of MEX3D. Expression levels were quantified using the 2-
∆∆Ct method with normalization to the stably expressed gene GAPDH, where ∆∆Ct = 
(Ct:siRNA-NC_A172 – Ct:GAPDH_A172) – (Ct:siRNA-MEX3D_A172 – Ct:APDH _A172). Error bars 
represent the standard deviation of the CT values.  
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Figure 4.4 MEX3D knockdown decreases cell proliferation in A172 glioma cells  
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Figure 4.4 MEX3D knockdown decreases cell proliferation in A172 glioma cells 
MEX3D was knocked down in A172 glioma cells using siRNA against MEX3D. 
Knockdown of MEX3D (bottom dashed line) leads to significant decrease in cell 
proliferation in A172 glioma cells after five days compared to the negative control si-
RNA transfected cells (top solid line) (p <0.001). The experiment was performed in 
triplicates, and the error bars represent the standard deviation between the triplicate 
experiments.  
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Figure 4.5 MEX3D knockdown increases cell invasion in A172 cells and U87 
cells 
A.  
B 
A172 
Negative Control  
U87 
MEX3D 
Knockdown
 80 
Figure 4.5 MEX3D knockdown increases cell invasion in A172 cells and U87 
cells 
MEX3D was knocked down using si-RNA against MEX3D in A172 cells and in U87 
cells. Negative control si-RNA (NC) served as the control. The cells were transfected 
and incubated for 24 hours. A. Ten random fields from each of the invasion assays 
were selected for cell counting using phase-contrast microscopy.  B. Error bars 
represent the standard deviation between the ten fields. Statistical significance of thde 
difference between the NC and the knockdown was determined using the Students t-
test. 
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CHAPTER 5: CONCLUSIONS  
The control of gene expression is pivotal in the context of molecular 
pathogenesis of a number of diseases, and thus is of critical relevance to public health. 
An array of cellular tools exist in controlling gene expression, including epigenetic 
effects, non-coding RNAs, and RNA-binding proteins. These tools are critical tools to 
the modern of public health, and are used in tandem with population-based studies. 
This work focuses on specific examples of non-coding RNAs and RNA-binding 
proteins, describing the effects of microRNA-618 and MEX3D, a post-transcriptional 
regulator, in cancer.  
MicroRNAs (miRNAs) form a class of highly conserved endogenous RNAs 
that inhibit gene expression and may act as oncogenes or as tumor suppressors, 
regulating extensive cancer-related gene networks. Here, we showed the association 
between a single miRNA, miR-618, and cancer-related pathways in HeLa cells. MiR-
618 was identified as a potentially oncogenic microRNA, controlling a number of 
cancer-related gene networks and pathways. Gain-of-function analysis reveals 
96differential expression of 110 transcripts following miRNA-618 transfection. 
Notably, three upregulated genes are well-studied oncogenes—KIT, JUN, and 
FOSB—and three downregulated genes are well-known tumor suppressors—PTPRO, 
STK11/LKB1, and IGFBP5. Interestingly, investigation using the Ingenuity Pathway 
Analysis software tool reveals alterations in multiple cancer-related and cell cycle-
related networks, including upregulated oncogenes in the top identified network 
“Post-translational modification, cellular development, cellular growth and 
proliferation” following miR-618 transfection. Further, miR-618 expression analysis 
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shows overexpression in HeLa cells compared to normal cervical cells. Our findings 
present evidence for a novel oncogenic miRNA, miR-618, that is involved in cancer-
related gene networks and is overexpressed in cancer. 
 RNA binding proteins also play a critical role in regulating gene expression, 
and are often critical in tumor development. This work also examined the role of a 
novel post-transcriptional regulator, MEX3D, in cancer. 97 The Oncomine online 
database reveals that MEX3D is overexpressed in a number of solid tumors, notably 
in glioma. MEX3D is 3.01-fold overexpressed in glioma cells compared to non-
cancerous, normal tissue. Kaplan-Meier survival analysis reveals that higher 
expression of MEX3D leads to poorer overall survival in overall glioma patients. 
Lastly, in a pilot case-control study of twelve glioma biopsies, we examined the 
effects of methylation in CpG sites in the MEX3D gene. The results were unclear, as 
we found a 3’UTR site that was 9.5% hypermethylated compared to normal tissue, a 
site in the body of the gene that was 24.8% hpyermethylated, and second site in the 
body that was 15.4% hypomethylated compared to normal tissue..  
Phenotypic studies reveal that MEX3D is responsible for two cancer 
phenotypes. Knockdown of MEX3D leads to increased cell proliferation and 
decreased cell invasion, suggesting that overexpression of MEX3D is responsible for 
increased cell proliferation and decreased cell invasion.  
 This study is the first to describe the effects of miR-618 and of MEX3D in 
cancer. The findings presented in this work lay the foundation for further mechanistic 
studies of miR-618 and MEX3D. More work is needed to identify the mechanisms of 
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oncogenesis controlled by these molecules. Our study indicates that miR-618 may be 
a biomarker for several types of cancer and warrants further investigation.   
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CHAPTER 6: Materials and methods 
6.1 Cell culture and miRNA transfection (Chapters 2 and 4) 
  HeLa cells (American Type Culture Collection) were cultured in Dulbecco’s 
modified Eagle medium (Invitrogen) with 10% fetal bovine serum (Invitrogen) and 
1% penicillin/streptomycin (Sigma-Aldrich). A172 cells will be purchased from 
ATCC (Manassas, VA) and maintained as monolayer cultures in 25 cm2 polystyrene 
flasks in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS). Cells will be incubated at 37ºC in a humid atmosphere 
containing 5% CO2 and subcultured every 2-3 days.  
6.2 miRNA transfection (Chapter 2) 
A synthetic miRNA mimic of hsa-miR-618 (5’-
AAACUCUACUUGUCCUUCUGAGU-3’) was synthesized by Qiagen for 
transfection. Cells were transfected with either the miR-618 mimic or a scrambled 
negative control (Qiagen) using the Lipofectamine RNAiMAX transfection reagent 
(Invitrogen), according to the manufacturer’s protocol. 120 pmol of miR-618 or 
negative control was mixed with 20 µl of RNAiMAX reagent and 2 ml OPTI-MEM 
(Invitrogen).  The mixtures were transfected with ~100,00 cells in 12-well plates, and 
cells were harvested 48 hours post-transfection. RNA was subsequently extracted for 
analysis using the RNeasy Mini Kit (Qiagen), according to the manufacturer’s 
protocol. 
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6.3 Genome-wide expression microarray (Chapter 2) 
Gene expression differences in cells transfected with the miR-618 mimic were 
interrogated by whole genome microarray (Agilent, Inc 41k chip, performed by 
MoGene). The miRNA transfection and microarray were conducted in two 
independent biological replicates. Due to the multiple comparisons inherent in the 
microarray analysis, the false discovery rate (FDR) method as described by 
Benjamini and Hochberg was applied in order to obtain an adjusted p-value (Q).98 
Transcripts with inadequate signal intensity (Intensity < 50) were discarded. 
Expression differences were considered to be statistically and biologically significant 
at Q < 0.05 and fold change ≥ |2|.  
6.4 Network Analysis (Chapter 2) 
 Genes that were differentially expressed from the miR-618 transfection were 
investigated for functional interrelatedness using the IPA software tool (Ingenuity 
Systems). This tool elucidates networks and functionality by using information in the 
Ingenuity Pathways Knowledge Base, which is a database of known functional 
interactions that have been previously identified in peer-reviewed publications.99 
Statistical significance was obtained by performing a Fisher’s exact test based on the 
hypergeometric distribution for each identified network to calculate the likelihood of 
obtaining at least the same number of related expressed genes by chance for the input 
gene set.  
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6.5 Expression analysis of miR-618 (Chapter 2) 
Total RNA from HeLa cells and End1 cells (American Type Culture 
Collection) was isolated using the miRNeasy Mini Kit (QIAGEN), with on-column 
DNA digestion.  To determine levels of mature miRNA, polyadenylated mature 
miRNA sequences were first generated and converted to cDNA using the NCode 
miRNA First-Strand cDNA Synthesis Kit (Invitrogen).  The cDNA was then 
amplified using a custom miR-618-specific forward primer (5’- 
AAACTCTACTTGTCCTTCT -3’) and a universal reverse primer targeting on the 
polyadenylated region of the miRNA.  Mature miRNA levels in HeLa cells relative to 
End1 cervical cells were assessed using the 2-∆∆Ct method with normalization to the 
stably expressed ncRNA U6B, where ∆∆Ct = (Ct:miR-618_HeLa – Ct:U6B_HeLa) – (Ct:LmiR-
618_End1 – Ct:U6B_End1).  All qPCR reactions were performed in triplicate on an ABI 
7500 Fast Real-Time PCR instrument (Applied Biosystems) using the Kapa 
Biosystems SYBR Fast qPCR kits (Kapa Biosystems) according to the 
manufacturer’s protocols.  
6.6 Oncomine Database Search (Chapters 3 and 4) 
 In order to determine differential expression of MEX3D in cancer vs. normal 
tissue, the Oncomine Database was searched on Sunday, March 30, 2014 using the 
search terms “MEX3D” and filtering for cancer vs. normal analysis 
(http://www.oncomine.org/). The following filters were added: threshold fold change 
of |2.0| and a threshold p-value of 1x10-4.     
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6.7 Kaplan-Meier curve (Chapter 4)  
MEX3D expression data from 273 glioma patients were analyzed using the Human Genome 
U133 Plus 2.0 Array. The Kaplan-Meier curve was calculated using a median-cutoff 
expression of 64.1 and two curves were calculated: a high group (n=143) with MEX3D 
expression greater than the median 64.1 value, and a low group (n=130) with MEX3D 
expression lower than the median 64.1 expression value. The Bonferoni method was to 
correct for multiple comparisons.  
6.8 MEX3D methylation analysis (Chapter 4) 
 The Illumina Custom Model, as implemented in the Illumina GenomeStudio 
software, was used to assess the statistical significance of methylation differences 
between glioma cases and controls at each CpG site. This model operates under the 
assumption that the methylation value β is normally distributed at each locus. The 
variance function is estimated for all values of β by repeatedly measuring loci with 
known methylation fractions ranging from 0 to 1, and then fitting a parabola to the 
standard deviation as a function of β. The standard deviation estimate is then given by 
s = Aβ2 + Bβ + C, where A = -0.1511, B = 0.1444, and C = 0.01646.  
P-values were calculated using the following formula:  
 
 
where z denotes the standard score of a two-sided normal probability distribution, βref 
and βcond denote the average β values for the reference (normal tissue controls) and 
condition (glioma tumor samples) groups, s2ref and s2cond denote the variances of βref 
p  =  z%|βcond  -­‐  βref|s2refNref + s2condNcond4 
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and βcond, and Nref and Ncond denote the sample sizes of the reference and condition 
groups. Due to the multiple comparative nature of our epigenome-wide analysis, P-
values generated by the array were corrected for multiple comparisons using the 
Benjamini-Hochberg method 100 based on the number of CpG sites measured 
(485,577) to minimize the probability of false positives. Only CpG sites exhibiting 
methylation differences with corrected P-values of <0.05 were considered as 
significantly altered.  
6.9 RNA interference and cell transfection (Chapter 4) 
In order to suppress MEX3D expression in glioma cells, MEX3D-specific 
small interference RNA (siRNA) was chemically synthesized from Invitrogen 
(Catalog no. 1299001). A negative control siRNA served as the control for the cancer 
phenotype assays (Invitrogen). A172 cells cells will be reverse transfected in 12-well 
plates with either siRNA or the siRNA control using LipofectAMINE RNAiMAX 
transfection reagent (Invitrogen, Carlsbad, CA).  Approximately 25,000 cells 
suspended in 10% FBS-supplemented DMEM will be added to a pre-incubated 
mixture of RNAiMAX (1 µl) and RNA oligo in each well to a final oligo 
concentration of 25 nM. Wells will be incubated at 37ºC and 5% CO2 for 72 hours 
prior to RNA isolation (RNeasy Mini Kit, QIAGEN, Valencia, CA). All transfections 
were conducted in biological triplicate. Total RNA from A172 cells (American Type 
Culture Collection) was isolated using the RNeasy Mini Kit (QIAGEN), with on-
column DNA digestion.  To determine levels of mature mRNA, polyadenylated 
mature mRNA sequences were first generated and converted to cDNA using the 
NCode mRNA First-Strand cDNA Synthesis Kit (Invitrogen).  The cDNA was then 
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amplified using a custom MEX3D specific forward primer (5’- 
CCAGGGCTGCAAGATCAAG-3’).  Mature mRNA levels in A172 cells were 
assessed using the 2-∆∆Ct method with normalization to the stably expressed gene 
GAPDH, where ∆∆Ct = (Ct:siRNA-NC_A172 – Ct:GAPDH_A172) – (Ct:siRNA-MEX3D_A172 – 
Ct:APDH _A172).  All qPCR reactions were performed in triplicate on an ABI 7500 Fast 
Real-Time PCR instrument (Applied Biosystems) using the Kapa Biosystems SYBR 
Fast qPCR kits (Kapa Biosystems) according to the manufacturer’s protocols.  
6.10 Cell proliferation assay (Chapter 4) 
Effects of MEX-3D on cell proliferation will be measured using a cell 
proliferation assay kit from Invitrogen (Cat. No C35006). This compares MEX-3D 
knockdown in A172 cells to A172 cells treated with the negative control siRNA. This 
assay measures cell proliferation by quantifying DNA to indicate a relative cell 
number, and will be performed according to the manufacturer’s protocols. Each time 
point was measure in triplicate and were measured in 24-hour intervals.  
 
6.11 Cell invasion assay (Chapter 4) 
 A172 cells and U87 cells were seeded into the upper wells of 24-well 
Transwell plates on Matrigel-coated (BD Biosciences Inc., San Jose, CA, USA) 8-µm 
poly(ethylene terephthalate) membranes (Millipore Corpo., Billerica, MA , USA) in 
DMEM without fetal bovine serum (FBS). The lower wells contained complete 
medium with 10% FBS.  After 48 h of incubation in a humidified atmosphere with 
5% CO2, the contents of the upper well content were removed using Q-tips. The 
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invasion chambers were processed following the manufacturer’s protocols, and the 
migrated cells were stained with haematoxylin (??). Ten random fields from each of 
the invasion assays were selected for cell counting using phase-contrast microscopy. 
6.12 Statistical analysis 
With the exception of differential gene expression analysis, network analysis, 
and methylation analysis using the statistical methods described above, all other 
statistical analyses were evaluated using the Student’s t-test. P <0.05 was considered 
to indicate a statistically significant difference.  
 
 
 
 
 
 
 
 
 
 
 	  	  
 91 
CHAPTER 7: SUPPLEMENTARY INFORMATION  
 
TABLES 
Supplementary Table S1. All identified differentially expressed genes by miR-618 
transfection with expression fold changes ≥ |2| 
Gene Symbol Descriptiona  Fold changeb 
AU145408 Unknown function 5.24 
A_24_P942036 Unknown function 4.66 
A_32_P6841 Unknown function 4.46 
AK026750 Unknown function 4.38 
CCDC66 Coiled-coil domain containing 66; encoded protein 
linked to progressive retinal atrophy 
4.30 
A_32_P233713 Unknown function 4.06 
TEX13B Testis expressed 13b 4.04 
A_32_P4882 Unknown function  3.79 
FOSB FBJ murine osteosarcoma viral oncogene homolog B. 
Encodes protein that can dimerize with proteins of the 
FUN family. Implicated in cell proliferation, 
differentiation, and transformation. 
3.62 
A_24_P611965 Unknown function 3.59 
PCDH1 Protocadherin 1; encodes membrane protein found at 
cell-cell boundaries.  
3.52 
HBBP1 Hemoglobin, beta pseudogene 1. 3.49 
NAIF1 Nuclear apoptosis inducing factor 1; encoded protein 
inhibits tumor cell proliferation by inducing apoptosis. 
3.41 
NM_052958 Unknown function 3.36 
CA441361 Unknown function 3.16 
FA2H Fatty acid 2-hyrdoxylase. Encoded protein catalyzes 
synthesis of 2-hydroxysphingolipids. 
3.13 
 92 
KRT18 Keratin 18; encodes type I intermediate filament chain 
keratin 18. Expressed in epithelial tissues and mutations 
in KRT18 have been linked to cryptogenic cirrhosis.  
2.99 
BF899060 Unknown function 2.93 
COL8A2 Collagen, type VIII alpha 2. This encoded protein is a 
major component of the basement membrane of corneal 
epithelium.  
2.90 
SAMD9L Sterile alpha motif domain containing 9-like 2.85 
JUN Jun proto-oncogene; Putative transforming gene of 
avian sarcoma virus 17. Encoded gene interacts with 
specific DNA to regulate gene expression.  
2.79 
KCNE4 Potassium voltage-gated channel, Isk-related family, 
member 4. Encoded protein is a type I membrane 
protein with a potassium channel.  
2.75 
BC063641 Unknown function 2.67 
W95609 Unknown function 2.67 
BIK BCL2-interacting killer (apoptosis-inducing). Encoded 
protein has pro-apoptotic activity and its expression is 
suppressed in the presence of survival-promoting 
proteins.  
2.66 
AI263083 Unknown function 2.66 
ZBED2 Zinc finger, BED-type containing 2 2.59 
THC2340539 Unknown function 2.57 
IL22RA1 Interleukin 22 receptor, alpha 1. Encoded protein 
belongs to class II cytokine receptor family and has 
been shown to be a receptor for IL22.  
2.52 
ABLIM3 Actin binding LIM protein family, member 3; protein 
contains LIM domain, double zinc finger. It plays roles 
in embryonic development, cell lineage determination, 
and cancer.  
2.50 
ENST00000379557 Unknown function 2.50 
SRRM3 Serine/arginine repetitive matrix 3 2.50 
THC2442829 Unknown function 2.44 
THC2409451 Unknown function 2.40 
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ENST00000320662 Unknown function 2.39 
THC2316768 Unknown function 2.38 
CPM Carboxypeptidase M; encoded protein is a membrane-
bound arginine/lysine carboxypeptidase and is 
associated monocyte differentiation  
2.38 
EDN2 Endothelin 2; encodes member of endothellin protein 
family of secretory vasoconstrictive peptides. 
2.36 
DCN Decorin; encoded protein is a small cellular or 
pericellular matrix proteoglycan that is a component of 
connective tissue, binding to type I collage fibrils and 
playing a role in matrix assembly.   
2.35 
BC038972 Unknown function 2.27 
KCNJ10 Potassium inwardly-rectifying channel, subfamily J, 
member 10. Encodes potassium channel that allows 
potassium to flow into, rather than out of, a cell.  
2.27 
AA586832 Unknown function 2.26 
CDH7 Cadherin 7, type 2; encoded protein is membrane 
protein that is a calcium dependent cell-cell adhesion 
glycoprotein  
2.26 
ANG Angiogenin, ribonuclease, RNase A family, 5; encodes 
protein that strongly mediates blood vessel formation  
2.25 
BE671182 Unknown function 2.25 
THC2398758 Unknown function  2.25 
KREMEN2 Kringle containing transmembrane protein 2. Encodes a 
high-affinity dickkopf homolog 1 (DKK1) 
transmembrane receptor and complexes with DKK1 
And lipoprotein receptor-related protein 6 (LRP6) to 
induce rapid endocytosis and removal of LRP6 from 
plasma membrane.  
2.25 
DESI2 Desumoylating isopeptidase 2  2.22 
THC2436337 Unknown function 2.21 
TM4SF1 Transmembrane 4L six family member 1; encodes 
protein of transmembrane 4 superfamily that mediates 
signal transduction to play a role in regulating cell 
development, activation, growth, and motility.  
2.21 
KIT v-KIT Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog; encodes human homolog of proto-
oncogene c-kit. Aberrant expression associated with 
 2.20 
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cancer.  
ANXA8 Annexin A8; encodes protein Ca2+ and phospholipid 
binding proteins. Encoded protein may function as an 
anticoagulant that indirectly inhibits thromboplastin-
specific complex. Overexpression of ANXA8 has been 
associated with acute myelocytic leukemia. 
2.19 
MAPK4 Mitogen-activated protein kinase 4; activated MAPK4 
translocates to nucleus to phosphorylate nuclear targets.  
2.17 
SGKL Serum/glucocorticoid regulated kinase family, member 
3; encoded kinase phosphorylates several target proteins 
and plays role in neutral amino acid transport and 
activation of potassium and chloride channels. 
2.17 
A_24_P919283 Unknown function 2.15 
NGEF Neuronal guanine nucleotide exchange factor 2.15 
FBXO2 F-box protein 2; encodes protein involved in 
phosphorylation-dependent ubiquitination. 
2.15 
LGSN Lengsin, lens protein with glutamine synthetase domain; 
encoded protein is localized to the lens and by be 
associated with cataract disease.  
2.14 
AI915259 Unknown function 2.14 
IFI27 Interferon alpha-inducible protein 27 2.14 
THC2282944 Unknown function 2.13 
ENST00000375256 Unknown function 2.12 
N34499 Unknown function 2.11 
ENST00000302001 Unknown function 2.10 
SMIM15 Small integral membrane protein 15 2.10 
BI963219 Unknown function 2.08 
AF086329 Unknown function 2.08 
PIGZ Phosphatidylinosital glycan anchor biosynthesis, class 
Z; encodes protein that localizes to the endoplasmic 
reticulum and is involved in 
glycosylphosphatidylinosital anchor biosynthesis.   
2.05 
AW440350 Unknown function 2.05 
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THC2265157 Unknown function 2.05 
H43551 Unknown function 2.04 
BM504117 Unknown function 2.04 
AF159295 Unknown function 2.04 
MX1 Myxovirus resistance 1, interforn-inducible protein p78; 
encoded protein is responsible for specific antiviral state 
against influenza virus infection.  
2.04 
FGFBP1 Fibroblast growth factor binding protein 1; Encodes 
secreted fibroblast growth factor carrier protein that 
plays major role in cell differentiation, proliferation, and 
migration. FGFBP1 has been linked to cancer, including 
pancreatic and colorectal adnenocarcinoma.  
2.03 
MIF Macrophage migration inhibitory factor (glycosylation-
inhibiting factor; encodes lymphokine involved in cell-
mediated immunity, immunoregulation, and 
inflammation.  
2.01 
ASB4 Ankyrin repeat and SOCS box containing 4; encoded 
protein is member of ankyrin repeat and SOCS box-
containing (ASB) family of proteins.  
2.01 
RNASE4 Ribonuclease, RNase A family, 4; encoded protein is 
member of pancreatic ribonuclease family. Plays 
important role in mRNA cleavage and has marked 
specificity towards the 3’ side of uridine nucleotides.  
2.01 
ATP8B3  ATPase, aminophospholipd transporter, class I, type 8B, 
member 3; encoded protein belongs to family of P-type 
cation transport ATPases, and to the subfamily of 
aminophospholipid-transporting ATPases. 
2.00 
MAFA v-maf musculoaponeurotic oncogene (avaian); MAFA is 
a transcription factor that binds RIPE3b, a conserved 
enhancer element that regulates pancreatic beta cel-
specific expression of the insulin gene.   
-2.02 
PRLH  Prolactin releasing hormone  -2.02 
A_24_P375751 Unknown function -2.05 
PTPRO Protein tyrosine phosphatase, receptor type, O; encodes 
member of R3 subtype family of receptor-type protein 
tyrosine phosphatases. This gene is believed to be a 
tumor suppressor, and its decreased expression has been 
associated with several types of cancer.  
-2.07 
PDGFRA Platelet-derived growth factor receptor, alpha 
polypeptide; encoded protein is a cell surface tyrosine 
-2.10 
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kinase receptor for members of the platelet-derived 
growth factor family. These growth factors are mitogens 
for mysenchymal clles. Mutations in this gene have 
been associated with tumor progression. 
TNRC18 Trinucleotide repeat containing 18 -2.11 
BC013423 Unknown function -2.17 
BQ015140 Unknown function -2.17 
DHH Desert hedgehog; this gene encodes member of 
hedgehog family that encodes signaling molecules. The 
protein may be involved in male gonadal differentiation 
and perineurial development. 
-2.17 
A_24_P862251 Unknown function -2.18 
HAUS1 HAUS augmin-like complex, subunit 1; encoded protein 
is a microtubule-binding complex involved in 
microtubule generation within the mitotic spindle.  
-2.18 
HOX-AS3 HOXB cluster antisense RNA3 -2.24 
GPHB5 Glycoprotein hormone beta 5; encodes cysteine knot-
forming polypeptide and a subunit of the dimeric 
glycoprotein hormone family. 
-2.29 
SLC35F5 Solute carrier family 35, member F5 -2.31 
ENST00000074056 Unknown function -2.32 
NM_173573 Unknown function  -2.34 
ARTN Artemin; this protein is a member of the glial cell line-
derived neurotrophic (GDNF) family of ligands and has 
neurotrophic properties.   
-2.37 
STK11 Serine/threonine kinase 11; regulates cell polarity and 
functions as a tumor suppressor. Mutations in the gene 
associated Peutz-Jeghers syndrome and other 
neoplasms.  
-2.38 
LRRC15 Leucine rich repeat containing 15 -2.40 
ARHGAP27 Rho GTPase activating protein 27; encodes a GTPases 
that is involved in many cellular processes.  
-2.44 
CLDN5 Claudin 5; encodes integral membrane protein and 
forms tight junctions. Mutations in this gene have been 
associated with velocardiofacial syndrome.  
-2.47 
C1QTNF5 C1q and tumor necrosis factor related protein 5; encodes 
protein that may be a component of basement 
-2.47 
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membranes and may play role in cell adhesion. 
Mutations in this gene have been associated with late-
onset retinal degeneration 
BX105253 Unknown function -2.65 
MATN3 Matrilin 3; encodes member of von Willebrand factor A 
domain containing family of proteins. Thought to be 
involved in forming filamentous networks in the 
extracellular matrices in several tissues. Mutations in 
this gene result in multiple epiphyseal dysplasia.   
-2.69 
GLTP Glycolipid transfer protein; encoded protein accelerate 
transfer of various glycosphingolipids and 
glyceroglycolipids between membranes.  
-2.79 
A_32_P185089 Unknown function -2.80 
EFCAB4A EF-hand calcium binding domain 4a -3.00 
CBX5 Chromobox homolog; encodes member of 
heterochromatin protein family. Enriched in the 
heterochromatin and associated with centromeres. Can 
bind to histones via methylated lysine residues and is 
involved in the formation of functional kinetochore.  
-3.36 
AVP Arginine vasopressin. This encoded proteins is a 
posterior pituitary hormone that acts as a growth factor 
and is involved in antidiuretic activity in the kidney. It 
can also cause vasoconstriction of the peripheral vessels.  
-3.62 
a Gene function description was summarized from information obtained from database Entrez Gene 
Summary. 
b All fold changes are statistically significant (Q<0.05; False Discovery Rate (FDR) <0.05).  
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Supplementary Table S2. Identified cancer-related differentially expressed miR-618 
targets 
Gene name  Expression 
fold changesa 
Cancer-related functionsb 
ANG 2.25 Tumorigenesis of cervical cancer cell lines, mammary tumor 
ANXA8L2 2.19 Carcinoma, adenocarcinoma, ovarian cancer; gonadal tumor 
BIK 2.66 Carcinoma, adenocarcinoma, uterine cancer 
C8ORF8/SGK1 2.17 Mammary tumor skin cancer 
CDH7 2.26 Skin cancer 
CLDN5 -2.47 Carcinoma, adenocarcinoma, uterine cancer 
DCN 2.35 Mammary tumor, arrest in G1 phase of colon carcinoma cells 
DESI2 2.22 Mammary tumor, carcinoma 
FGFBP1 2.03 Epidermal hyperplasia 
FOSB 3.62 Mammary tumor, carcinoma, ovarian cancer, gonadal cancer  
HMGB1 2.04 Carcinoma, liver cancer, large cell lymphoma, Non-Hodgkin’s 
lymphoma, Hodgkin’s lymphoma  
HUWE1 2.04 Mammary tumor, carcinoma, head and neck cancer, liver, 
cancer, benign neoplasia, pancreatic tumor, lung cancer, 
pancreatic cancer, carcinoma in the lung, thyroid carcinoma 
IFI27 2.14 Carcinoma, ovarian cancer, gonadal cancer, head and neck 
cancer, skin squamous cell carcinoma 
IGFBP5 -2.02 Carcinoma, adenocarcinoma, head and neck cancer, benign 
neoplasia, pancreatic tumor, binding of mammary tumor cells, 
leiomyomatosis, mucoepidermoid carcinoma, metastatic 
colorectal cancer  
IL22RA1 2.52 Carcinoma 
JUN 2.79 Mammary tumor, carcinoma, ovarian cancer, gonadal tumor, 
uterine cancer, skin cancer, squamous cell tumor, large-cell 
lymphoma, Non-Hodgkin’s lymphoma, non-Hodgkin’s 
lymphoma, head and neck cancer, benign neoplasia, lung 
cancer, skin squamous cell carcinoma, leiomyomatosis, 
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leukemia, bone marrow cancer 
KCNE4 2.75 Leukemia, bone marrow cancer 
KIT 2.20 Mammary tumor, carcinoma, adenocarcinoma, ovarian cancer, 
gonadal cancer, skin cancer, liver cancer, large-cell 
lymphoma, Non-Hodgkin’s lymphoma, head and neck cancer, 
benign neoplasia, pancreatic tumor, lung cancer, carcinoma in 
lung, thyroid carcinoma, leiomyomatosis, leukemia, bone 
barrow cancer, dysgerminoma, uticaria pigmentosa, 
chordoma, aggressive fibromatosis, mixed germ cell tumor, 
seminoma, melanoma, sporadic mastocytosis, sarcoma, 
systemic mastocytosis, islet-cell carcinoma, 
neurofibrosarcoma, primary peritoneal cancer, gastrointestinal  
stromal tumor, Fallopian tube cancer, testicular cancer 
KRT18 2.99 Carcinoma, adenocarcinoma, uterine cancer, head and neck 
cancer, mucoepidermoid carcinoma, metastatic colorectal 
cancer  
MAFA -2.02 Carcinoma, squamous cell tumor 
MATN3 -2.70 Carcinoma, liver cancer 
MIF 2.01 Carcinoma, ovarian cancer, gonadal cancer, sarcoma 
MX1 2.04 Epidermal hyperplasia 
PDGFRA/B -2.10 and 
+2.04, 
respectively 
Mammary tumor, carcinoma, adenocarcinoma, ovarian cancer, 
gonadal cancer, liver cancer, head and neck cancer, benign 
neoplasia, pancreatic tumor, lung cancer, pancreatic cancer, 
carcinoma in lung, leiomyomatosis, leukemia, bone marrow 
cancer, sarcoma, systemic mastocytosis, islet-cell carcinoma, 
neurofibrosarcoma, primary peritoneal cancer, gastrointestinal 
stromal tumor, Fallopian tube cancer 
RNASE4 2.01 Carcinoma, adenocarcinoma, uterine cacner 
STK11/LKB1 -2.38 Carcinoma, adenocarcinoma, gonadal tumor, uterine cancer, 
skin cancer, squamous cell tumor, pancreatic tumor, lung 
cancer, pancreatic cancer, carcinoma in lung, testicular cancer, 
adenoma malignum, Peutz Jagher syndrome 
TM4SF1 3.16 Carcinoma, adenocarcinoma, skin cancer, liver cancer, 
metastatic colorectal cancer 
a All fold changes have a Q value of <0.05.  
b All associations between the transcript and disease have a p-value of <0.05.  
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Supplementary Table S2: Affected genes related to hepatotoxicity and 
hepatocellular carcinoma 
Gene Effect Fold changea 
TM4SF1 Upregulated 3.16 
KIT Upregulated 2.20 
PDGFRB Upregulated 2.14 
HUWE1 Upregulated 2.04 
HMGB1 Upregulated 2.04 
PDGFRA Downregulated -2.10 
MATN3 Downregulated -2.70 
a Overlap p-value: 5.72 x 10-3   
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Supplementary Figure S1: Secondary structure prediction of pre-miR-618. 
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Supplementary Figure S1: Predicted secondary structure of pre-miR-618. 
Mature miR-618 is highlighted in red. Base pairs are colored according to the 
probability of predicted accuracy. Red represents >99% probability, whereas blue 
represents 50-60% accuracty. Secondary structure generated using RNAstructure.101  
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Supplementary Figure S2: Differentially expressed transcripts following miR-618 
transfection in the “Cellular movement, cell death and survival, and cell cycle” 
network.
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Supplementary Figure S2: Differentially expressed miR-618 targets in the 
“Cellular movement, cell death and survival, and cell cycle” network. This 
network was identified by the Ingenuity Pathway Analysis software as significantly 
associated with the set of transcripts with altered expression following the 
introduction of pre-miR-618 (pooled p-value = 8.61 x 10-7 and FC ≥ |2|). 
Overexpressed transcripts are indicated in red, and underexpressed transcripts are 
indicated in green.  
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